And the lockdown continues .. we are in midst of a life threatening virus I have taken both the shots of vaccine covishield ..

please stay safe ..I hardly leave my home I decided not to go for Haridwar Kumbh I was broke .. too.

Best Wishes to all of you..

Media used was Hichrome UTI Agar in which various organisms like Escherichia coli (pink), Providencia (green), Enterococcus faecalis (bluish mucoid), Klebsiella pneumoniae (bluish green) Chrysobacteriom indoligenes (yellow), Candida albicans (white) give various colours upon growth. I specifically utilised this property to display the art on the agar plate. Here the upper part of the petri plate shows virulent Corona virus which are equipped to invade and infect a new healthy host. However with the use of various covid appropriate practices on part of an individual like use of mask,social distancing and vaccination with any one type of vaccine (Pfizer, Moderna, covishield, covaxin etc) one can defend against infection efficiently. Besides this hand washing with soap and the use of alcohol based sanitiser one can effectively neutralise the virus thereby protecting oneself. Hence implementation of these simple yet very effective techniques routinely will help us in our fight against this pandemic. I have tried to emphasise the significance of trees and plantation for our well-being. The oxygen produced by trees is essential for life and survival.

www.cnbc.com/2022/01/28/the-new-bapoint2-omicron-subvaria...

 

The latest Covid variant is 1.5 times more contagious than omicron and already circulating in almost half of U.S. states

 

Key Points

 

■ The omicron subvariant, known as BA.2, is 1.5 times more transmissible than the original omicron strain, according to Danish scientists.

■ The U.K. Health Security Agency on Friday said BA.2 has a “substantial” growth advantage over the original omicron, known as BA.1.

■ Nearly half of U.S. states have confirmed the presence of BA.2 with at least 127 known cases nationwide as of Friday.

 

There are already dozens of cases across almost half of the U.S. of a new Covid subvariant that’s even more contagious than the already highly transmissible omicron variant.

 

Nearly half of U.S. states have confirmed the presence of BA.2 with at least 127 known cases nationwide as of Friday, according to a global data base that tracks Covid variants. The Centers for Disease Control and Prevention, in a statement Friday, said although BA.2 has increased in proportion to the original omicron strain in some countries, it is currently circulating at a low level in the U.S.

 

The subvariant is 1.5 times more transmissible than the original omicron strain, referred to by scientists as BA.1, according to Statens Serum Institut, which conducts infectious disease surveillance for Denmark.

 

The new sublineage doesn’t appear to further reduce the effectiveness of vaccines against symptomatic infection, according to the U.K. Health Security Agency.

 

“Currently there is no evidence that the BA.2 lineage is more severe than the BA.1 lineage,” CDC spokesperson Kristen Nordlund said.

 

BA.2 overtook the original omicron as the dominant variant in Denmark over the course of a few weeks, said Troels Lillebaek, the chairman of the Scandinavian nation’s committee that conducts surveillance of Covid variants.

 

BA.1 and BA.2 have many differences in their mutations in the most important areas. In fact, the difference between BA.1 and BA.2 is greater than the difference between the original “wild strain” and the Alpha variant, which was the first major mutation to take root across the world.

 

The BA.2 variant has five unique mutations on a key part of the spike protein the virus uses to attach to human cells and invade them, Lillebaek told CNBC. Mutations on this part of the spike, known as the receptor binding domain, are often associated with higher transmissibility.

 

The U.K. Health Security Agency on Friday said BA.2 has a “substantial” growth advantage over the original omicron. The sister variant spread faster than the original omicron in all regions of England where there were enough cases to conduct an analysis, according to the agency.

 

However, a preliminary assessment found that BA.2 doesn’t appear to reduce the effectiveness of vaccines any more than the original omicron. A booster dose was 70% effective at preventing symptomatic illness from BA.2 two weeks after receiving the shot, compared with 63% effectiveness for the original omicron strain.

 

The World Health Organization has not labeled BA.2 a variant of concern. However, WHO officials have repeatedly warned that new variants will arise as omicron spreads across the world at an unprecedented rate. Maria Van Kerkhove, the WHO’s Covid-19 technical lead, warned on Tuesday that the next Covid will variant be more transmissible.

 

“The next variant of concern will be more fit, and what we mean by that is it will be more transmissible because it will have to overtake what is currently circulating,” Van Kerkhove said. “The big question is whether or not future variants will be more or less severe.”

 

Lillebaek said there is not enough data yet to determine whether BA.2 is able to reinfect people who caught the original omicron. However, prior infection would likely provide some crossover immunity to BA.2.

 

Pfizer and Moderna started clinical trials this week on omicron-specific shots amid growing concern that new variants will emerge as immunity induced by the original vaccines wanes.

 

New Covid cases are increasing in Denmark, with more than 50,000 new infections reported on Friday in a country of 5.8 million people, according to the country’s health ministry. Lillebaek said it’s safe to assume that BA.2 is driving the increase of new infections in Denmark right now.

 

New hospital admissions in Denmark rose by 12 for a total of 967 patients who are Covid positive. Lillebaek said this increase is likely within the limits of what the health system can manage. However, he noted that 80% of Danes are fully vaccinated and 60% have received booster shots.

 

“If you are in a community or living in a country where you have a low vaccination rate, then you will have for sure more admissions to hospital and more severe cases and then more going to ICU,” he said.

 

In the U.S., about 67% of those eligible are fully vaccinated, according to data from the CDC.

 

seekingalpha.com/article/4482445-novavax-several-positive...

 

Novavax Marches Ahead With Several Positive, Major Developments

 

Summary

 

» Novavax said it's on track to make 200 million doses per month by March. In early January, the Serum Institute had already made 200 million Novavax doses.

» A consortium says over 18 billion high-quality vaccine doses are likely needed in 2022. Novavax says, excluding China and Russia and children under 12, about 11.6 billion doses are needed.

» Several large macro factors unrelated to Novavax and vaccines have hurt it and other vaccines stocks in recent weeks. I expect most of those to reverse and help the price.

» The majority of experts say additional variants will emerge and could be more severe or escape immune protection, and keep Covid from becoming endemic this year.

» Even if Covid becomes endemic, I think major annual Covid revenues will occur. Also, this year's earnings alone plus its strong pipeline make Novavax worth more than its current valuation.

 

Important positive developments and a much lower share price have made Novavax (NASDAQ:NVAX) an even better buy. The majority of the developments I cover below have not been reported at all by any Western news outlets or only barely covered by one outlet. Thus, strong results in the works are really under the radar. As they come into view and things are better than perceived, I think the share price will rise. I believe reading this will give you an edge to increase your alpha. In addition, I describe some macro factors that have irrationally driven the recent price decrease that have little or nothing to do with Novavax's situation. In the coming weeks, I think investors will realize these macro factors shouldn't affect Novavax, which will also help the price go higher.

 

I've encouraged people to buy on pullbacks and sell gradually on rebounds. The day I published my last article the price dropped to $112.52, and two trading days later it hit $137.66, for an increase of 22.3%. So I'm hoping people followed my suggestion and took a chunk of profits at 15% to 20% gain. In just two days, that's double the average annual gains of the market.

 

Since $137.66, the stock has pulled back to below ~$80, representing a great buying opportunity. The consensus short-term price target is $270, with a high of $315 and a low of $208. From ~$80, reaching the consensus would be a gain of more than 230%. Just reaching the lowest price target would be a gain of 134%.

 

A month ago, the price was at $236.5. A return to that level would be an increase of 166% from here. I think that is probable in the coming months since Novavax is in a much better position now than a month ago. Here I will describe several major positive developments that have improved Novavax's situation even further.

 

The Serum Institute already produced 200 million Novavax doses by early January

 

In a TV interview on January 10th, an India Covid Task Force member, Dr. Purvez Grant, said the Serum Institute (SII) has "already got 200 million doses ready" of Novavax, which uses the brand Covovax in India. Grant is the head of a hospital chain in the same city as SII with 750 doctors and the largest number of ICU beds in India. It has won many awards including the best medical tourism hospital in India. It has been purchasing AstraZeneca doses directly from SII, plus vaccines for other diseases.

 

In early December, the SII CEO said he had already developed capacity to make 150 million Novavax doses per month, and would start making that quantity upon authorization. He also planned to keep tens of millions of doses in stock in advance. Within a day of that, the WHO's chief scientist said on Indian TV that she expected the WHO to approve Novavax around December 16th. She said the EU and UK were reviewing it, and she supported approval.

 

As the main supplier of vaccines to low and middle-income countries (LIMCs), SII has a close relationship with the WHO. I think after hearing the WHO news, they assessed the situation, spoke to their contacts and determined Novavax would be approved and began the 150 million per month production a week before WHO approval. Thus they were able to have 200 million doses by January 10th. Watch the whole interview here.

 

By January 4th, only one week after India's EUA, SII had already sent 20 million doses to the Indian government. The government's lab had already tested and dispatched 10 million doses to the authorities for public use, and was close to being done testing the next 10 million. An official said SII would continue regularly sending batches of 10 million doses. It's been 3 weeks since then, so the number is likely much higher.

 

On January 12th the Novavax CEO said: "We're at a rate in this quarter of over 200 million doses per month by the end of this quarter," which is 2.4 billion doses per year. As I've detailed here, if Novavax and its partners bring their facilities to maximum capacity, they can make about 4 billion doses per year. I believe they will use much of this for production of a combination Covid-flu vaccine if trials for it are successful, which I expect they will be. Some space will also be used for its solo flu vaccine.

 

The IMF-WHO forecast is for 245 million Novavax doses delivered to high-income countries by June

 

I think the most accurate vaccine supply and delivery tracker is the IMF-WHO tracker that is updated weekly "in collaboration with countries and areas, suppliers, immunization, health and financing partners." It breaks expected deliveries out by month and by 3 categories of countries. AMC91 refers to the 91 poorest countries of the world.

 

The tracker correctly shows that in December, only a very small amount had been delivered overall. It forecasts that Covax deliveries will ramp up in the spring with about 70 million doses delivered per month to Covax in May and June. This is in line with poor countries saying they are setting up mass vaccination campaigns, but need time to do so.

 

The chart breaks out AMC91 deliveries by Covax and bilateral. Bilateral is when a country buys doses directly from a vaccine maker. For the end of Q1, it shows 200 million doses delivered to high-income countries. The Indian government's export tracker shows SII has already shipped 16 million doses to the EU, including 4 shipments in the last week. That is already 59% of the EU's Q1 order of 27 million. The first EU delivery was January 10th. Shipments to Australia are expected soon. Novavax said they'll have 100 million U.S. doses ready to deliver by EUA. The Fujifilm CEO said their UK facility made 60 million doses by the start of December. Thus I think the IMF-WHO forecast is right.

Consortium of experts says over 18 billion high-quality vaccine doses are likely needed in 2022

 

Last week, a consortium of experts released a report saying about 20 billion more high-quality Covid shots are needed in 2022 to vaccinate the world. It notes currently Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) are the only high-quality shots. As Novavax is rolled out around the world, I think there will soon be a third.

 

The report notes the largest number of people vaccinated so far received inactivated vaccines such as Covaxin and Sinovac. It notes: "multiple comparative studies showed statistically significant inferiority of inactivated vaccines" against infection, severe disease and death; Plus rapidly declining antibodies and a lack of cross-protections against variants.

 

One study of Sinovac found "no neutralization activity was detected" against the Beta and Omicron variants. It says "significant evidence" shows people who received either these inferior vaccines or one dose of Johnson & Johnson (NYSE:JNJ) will need two doses of a high-quality vaccine to have suitable immunity. As a result, it estimates that most likely 10.5 billion high-quality doses are needed in 2022 to boost people who were vaccinated last year.

 

The report also notes 3.3 billion people have not been vaccinated at all, and will need two initial doses and a booster several months later. That's 9.9 billion doses. The two numbers combined are 20.4 billion. It describes other factors that could mean 22 billion doses are needed this year. If we conservatively reduce that amount by 35% it is 14.3 billion. If we reduce it by 50%, it is 11 billion doses.

 

This report was not covered by most news outlets. That plus other things make me think most of the news outlets are missing the boat on 2022 and 2023 vaccine sales. The majority of infectious disease health experts say new variants will emerge, and it is likely one will escape half of or all of our immune protection. They also say we can't predict if new variants will be more severe.

 

I think the reason most media outlets are not giving much coverage to this is because it's depressing to think about, so their minds push it to the side. But from an investment perspective, I think it's been a mistake for people to sell (or short) vaccine stocks in recent weeks primarily because they think the pandemic is over, or Covid vaccine sales will be very low going forward.

 

Novavax shows strong demand, including the EU already ordering 250% more than its minimum

 

Novavax's market research found that even if China and Russia are excluded, 11.6 billion doses are needed in 2022. That doesn't include fourth doses that many people will probably need by the end of 2022. That also doesn't include the roughly 1.72 billion people under 12, which is 22% of the world. Two doses for them are 3.44 billion doses, and three are 5.16 billion doses.

 

The CEO of Gavi (the co-leader of COVAX) on January 13 said demand for Novavax in Europe was strong: "We're beginning to see a lot of demand in European countries for this vaccine.... It's been a very effective booster." Further proof is the EU recently expanded its order from 27 million doses in Q1 to add another 42 million doses in Q2. That's 250% more than the EU's minimum commitment of 20 million. It's 35% of the maximum number of 200 million doses. At this pace, the EU would use up all 200 million in 17 months, and need to buy more.

 

Germany is planning to do a country-wide vaccine mandate, as 60% support it, only 32% oppose it, and the head of the country is "firmly convinced" it is the only way to end the pandemic. I think Germany will require 3 doses, as it already requires that for entry into bars and restaurants. 21 million Germans are unvaccinated, so 3 doses for them are 63 million doses.

 

51% of unvaccinated Germans cite dislike of the RNA and adenovirus technologies as a reason for not being vaccinated. If they plus 9% of the others prefer Novavax, that's 60%, or 38 million doses. 70% is 44.1 million doses. About 20 million of the vaccinated haven't received a booster. About 1.4 million need two more shots. If 15% of those groups prefer Novavax, it is 3.4 million doses.

 

I think these are the reasons why Germany is getting 34 million Novavax doses this year, which is its entire allotment of the 200 million, split based on population sizes. If some smaller EU countries don't take their full allotment, I think Germany will take them because besides the above, they will likely need boosters in 2023. But I believe other EU countries will take their whole Novavax allotment as a low-cost insurance policy that would save large numbers of lives and great economic losses if a variant escapes RNA vaccines, while Novavax's provides protection.

 

A possible risk is if Novavax only delivers a low number of doses in Q1 such as 100 million. That said, don't believe inaccurate claims that Novavax guided for 80 million doses. In fact, they've said until more EUAs come in, they aren't yet giving guidance for total numbers of deliveries. They simply gave examples of Q1 deliveries to two entities (the EU and Covax) that already approved it. Adding these two and claiming it is Q1 guidance isn't accurate. For example, it clearly doesn't include the 20 million doses already delivered to the Indian government or the 40 million SK Bio is planning to deliver to Korea. In addition, the CEO clearly said: "In the first quarter, we expect to see an acceleration in shipments as more authorizations are received."

 

Novavax displayed a slide of its orders totaling about 2 billion doses. This doesn't include any doses from India because it hasn't placed an official order yet.

 

Grant, of the Indian task force, said he thinks Novavax will soon be the vaccine of choice: "I think very shortly this new vaccine will be given to everybody. .... So this vaccine is what is going to come out in a very, very big way very, very shortly." If yes, the number above could be as much as 700 million doses higher.

 

This week, a Korean stock analyst said SK Bio has made supply agreements with Thailand and Vietnam that are large enough to increase SK Bio's price target. They are classified as upper middle-income and their combined populations are 163 million. Novavax's chief commercial officer John Trizzino said on January 12th: "the trend line is that there's an increase in demand for vaccines, not a decrease."

 

Australia's APA of 51 million doses and the EU's H1 order of 69 million may mean $2 billion in profits

 

Last week Australia approved Novavax. The head of its drug agency said there was strong public interest because it relies on older technology than mRNA. Australia has an APA to buy at least 51 million doses with an option for an additional 10 million. I've read 7 Covid APAs between OWS vaccine companies and governments (the UK, the EU, etc.). None can be cancelled except in very unusual situations such as breach, fraud or acts of God. Likewise, countries cannot delay receipt of the order until the next year. Even in a breach, companies have 30 days to remedy it. Most of Novavax's 2 billion doses ordered are APAs.

 

On its earnings call, Novavax said doses from SII to higher-income countries are being made on a contract (NASDAQ:CDMO) basis, in which Novavax pays a fee per dose and keeps all profits. For example, they said: "And we've also signed an agreement with [SII] if we want for them to make product for high income markets, and so we have a CDMO agreement with them." CDMO means they are done for a set fee. B. Riley also said Novavax keeps all profits on SII doses to high-income countries. B. Riley said concerns about Novavax production are unwarranted, and it would capture "meaningful share" of the $60B+ 2022 Covid market.

 

Novavax has said it's charging high-income countries $20 per dose. In August, Denmark issued a statement revealing the price to the EU is $20.9 per dose. Danish news outlets reported the same. Then Denmark realized the price is confidential and took it down. It's possible the price is 15% to 20% higher than $20.9 if it doesn't include the advance payment the EU usually makes to vaccine companies.

 

I estimate Novavax is paying SII ~$3 per dose, giving $17.9 profit per dose. Including only the 51 million Australia doses, the 69 million H1 EU doses and ~20 million H2 Germany doses, that would be $2.51 billion in profits. Even if it's paying SII $4 per dose, it would be $2.37 billion in gross profits. That's only some of the orders.

 

Total revenues and profits this year

 

Novavax's quarterly 10-Q says that from its existing APAs alone, there is $7.2 billion due to it just for completing the APAs' minimum obligations. Novavax says it expects to fulfill those by this September.

 

That doesn't include optional doses in the APAs. For example, it only includes 20 million guaranteed EU doses. The EU has already ordered 49 million more than that in H1 plus Germany's roughly 20 million in H2. That's 69 million more than the minimum. At $20.9 per dose, that adds $1.44 billion in revenues for a total of $8.64 billion.

 

In 2021, Novavax received $1.26 billion of deferred revenue, which will be recognized this year. That would bring total revenues to $9.9 billion. That doesn't include royalty profits from its licensing agreements. For those, SII is expected to sell 750 million doses to Covax and 250 million to LIMCs. SK Bio is slated to sell 40 million to Korea plus unknown amounts to Thailand and Vietnam. Takeda has an APA for Japan to buy 150 million. If Novavax gets an average of $3 royalty per dose, the above doses would add $3.57 billion, for total revenues of $13.47 billion. Feel free to adjust any of those numbers up or down.

 

Last quarter, its expenses were $486 million. Its Q3 expenses dropped due to no longer having to conduct two huge phase 3 trials. Using 2022 expenses of $2 billion, earnings would be $11.47 billion. If its expenses increase by 50% over last quarter to be $2.9 billion total, its earnings will be $10.57 billion. If expenses double to be $3.89 billion, earnings will be $9.58 billion. That alone is far higher than the current market cap. At a PE of just 5, it would be a valuation of $47.9 billion.

 

The earnings above don't include Vietnam or Thailand orders, nor any EU doses in H2 except Germany, nor any new orders from countries throughout Latin America and Africa and some of Asia that have not placed orders yet.

 

A potential risk to examine is if Novavax does much lower than the numbers above. If Novavax does a full 50% less, earnings would still be between $4.79 billion and $5.73 billion. That's roughly the current market cap, and doesn't include sales of its Covid vaccine beyond 2022, its flu vaccine and its probable malaria vaccine and RSV vaccines. Thus, while there is some risk to the stock going as high as I expect, I think the risk of losing money at this valuation is very low. And the upside is excellent.

 

Novavax is "extremely effective" against Omicron

 

Novavax notes a strength of its vaccine is "strong cross-protection against variants." A main explanation is it presents a full-length spike protein to the immune system, while the RNA and adenovirus vaccines only present a portion of the spike. The problem is that portion, which is located at the top of the spike, regularly mutates and thus can more easily evade those narrow vaccines.

 

Novavax has the top part of the spike, and also the full length of the stalk, aka the stem or trunk. This diagram shows the top portion and the stalk of the full-length spike proteins on a Covid virus

 

Novavax gives antibodies that can recognize Covid by either its top part or its stalk, and thus neutralize it either way. With the RNA and adenovirus vaccines, if the top part mutates too much, the virus can escape. They don't even attempt to recognize the stalk.

 

Another major way this helps Novavax is the stalk mutates much less than the top. Thus, Novavax can recognize Covid in ways the RNA and adenovirus vaccines cannot, plus those ways are much less subject to change. The top part of the spike can mutate significantly, yet still infect people - as Delta and Omicron both showed. But if the stalk mutates too much, the whole spike no longer functions and that mutation won't survive.

 

An analogy is if police are told to find a suspect with long blond hair, brown eyes, glasses and earrings. But the suspect changes all of those. That is akin to vaccines that target only the top of the spike. Novavax does that too, but also knows the suspect is 5'4", weighs 140 pounds and has a limp. The suspect can't really change those things, so Novavax's probability of catching the suspect is far higher. Novavax has two sets of things to look for, and one set doesn't change much.

 

I think this is why Novavax's flu vaccine (Nanoflu) beat the previous best flu vaccine (Fluzone) by 20% to 66% in three head to head trials, including in cross-protection against drifted strains. Nanoflu is poised to take a sizable share of the flu market, which is slated to double to $9.5B by 2027. With Nanoflu better than Fluzone and SII's tremendous sales and distribution network, I think Nanoflu will get over 20% of it. That would be more than $1.9 billion in annual sales with strong margins.

 

At a price to sales multiple of 7X, Novavax's valuation would be $13.3 billion. If it only gets 12% share, it would be $1.14 billion. At a 7x multiple, it'd be a valuation of $8 billion, which is more than 25% higher than the market cap now. That would be a gain of 5% per year without including any sales from Covid, malaria or RSV. It also doesn't include the over $6 billion in cash it will likely have by year end. So even if zero Covid sales occur from 2023 onwards, I think Novavax will be worth much more than now.

 

Novavax's strength in cross-protection against new variants was further demonstrated in the stellar results of its booster study showing its vaccine produced high levels of neutralizing antibodies against Omicron. Its booster increased antibodies against the omicron 73.5-fold, and was more effective in stopping Omicron from entering cells than other vaccines.

 

Moreover, SII has been conducting a phase 3 efficacy trial of Novavax since last February. Grant, India's task force member, said SII told him the Novavax vaccine is "extremely effective" against Omicron, in the vicinity of 90%.

 

He added: "I think it is extremely important that everybody be given the third shot and as quickly as possible. Now, what we have found is that people who are taking Covishield, the third shot has not been so effective. But the new vaccine that is coming out from Serum Institute, Covovax, is very, very effective. In fact, against the Omicron virus, if you've taken the new vaccine of Serum, we are finding fantastic results."

 

I think most investors didn't see the interview on Indian TV. When SII announces the results, it could be a game-changer by making Novavax the only vaccine with high efficacy against Omicron. Novavax has also been doing a large booster trial during the Omicron wave in the US. I expect it will announce results in March or April.

 

It's incorrect to predict Covid is becoming endemic or that future variants won't be more severe

 

In September, a physician wrote: "Covid will soon be endemic..." and "widespread immunity, vaccinated and natural, will bring control and a full return to normal". Since then, the delta and omicron waves have killed another 180,000 in the US. Now, some media outlets and officials are repeating the same mistake by predicting Covid will be endemic this year.

 

Aris Katzouraki, an Oxford professor and editor of the journal BMJ Evolutionary Biology, wrote: "Rosy assumptions endanger public health.... There is a widespread, rosy misconception that viruses evolve over time to become more benign. This is not the case. .... Thinking that endemicity is both mild and inevitable is more than wrong, it is dangerous: it sets humanity up for many more years of disease." For example with Covid, "most transmission happens before the virus causes severe disease." He noted Alpha and Delta were both more severe than the original.

 

Dr. Stuart Campbell Ray, an expert at Johns Hopkins University agrees its a myth. He added that with both omicron and delta circulating, people could get double infections that spawn "Frankenvariants."

 

The vast majority of experts say four things: 1) Many new variants will emerge; 2) They may be more severe; 3) They may be more infectious; 4) They will likely escape our acquired immunity, either due to mutations or waning immunity. If you're basing your investing on assumptions that any of those aren't true, view this page of 30 prominent experts saying they are true. They include the head of the Mayo Clinic's vaccine division, the head of the WHO and numerous others.

 

Experts say a problem is trillions of mutations are occurring around the world every day, which makes it fairly easier for Covid to escape our developed immunity. Dr. Luis Ostrosky, an infectious disease expert, said: "I see Omicron as our kind of final warning shot." He thinks if countries don't do something "drastic and permanent," Covid will mutate to completely escape vaccines and therapeutics.

 

Endemic means widespread, ongoing disease and most likely high vaccine revenues

 

Katzouraki said: "The word 'endemic' has become one of the most misused of the pandemic. And many of the errant assumptions made encourage a misplaced complacency. .... a disease can be endemic and both widespread and deadly. .... Endemic certainly does not mean that evolution has somehow tamed a pathogen so that life simply returns to 'normal'."

 

If it becomes endemic, experts say people will probably need boosters every one to two years. The head of Mayo's vaccines division recently said: "If you got your flu vaccine this fall... then you got vaccinated against a variant of influenza that first showed up in 1918. So, a hundred-plus years later, we're still vaccinating against that," Poland adds. "One hundred years from now, our great, great, ... great grandchildren will be getting immunized against coronavirus."

 

If he's correct, it will result in huge amounts of revenues for vaccine companies. Novavax getting even 10% of that market would make its valuation far higher than now. Market research firm GlobalData forecasts Novavax will have annual Covid sales of $7 billion in 2027. At a sales multiple of 6x, that would be a valuation of $42 billion, about 900% higher than now, not including Nanoflu and other vaccines.

 

Omicron has resulted in people missing work, economic losses and high numbers of hospitalizations and deaths. On January 23rd, the 7-day average death rate in the US was 2,174 deaths per day., more than the worst average of the Delta wave.

 

A recent Israeli study found people over 60 who get a 4th dose have 300% more resistance to serious illness than people who didn't get a 4th dose. That means people under 60 probably have improved resistance of at least 100% and 200%. In addition, the more months people are past their 3rd dose, they will receive an even higher benefit from the 4th dose.

 

In the study, people got 4th doses relatively soon after the 3rd doses, but they received a big benefit. People who have gone an additional 2 to 6 months longer since their 3rd dose will probably receive a greater benefit. I think this data indicates 4th doses will become the norm in the majority of high-income and middle-income countries during the course of this year.

 

A statement by an EU regulator was misinterpreted. He said boosters are "not something that we can think should be repeated constantly" because doing so could dampen immune responses. This was misinterpreted as every 6 to 12 months, even though constantly implies far more often. So he removed the statement and later clarified the EU's position: immune responses might only be dampened if boosters were given at "very short" intervals, and even then, it would only be "potentially making the vaccination a little bit less efficient over time."

 

He said boosters are successfully reducing severe disease and hospitalization. He urged people to "get a booster shot as soon as possible and now." He also said annual boosters each fall may be the best approach. Countries who are doing 4th doses or have decided to do so include Denmark, Israel, Hungary, Chile and Sweden. Moderna just reported its booster rapidly wanes after 6 months, further evidence that fourth doses are needed.

Why South Korea giving SK Bio and Novavax full BLA approval is important

 

The Korean drug agency recently gave full approval to the Novavax vaccine. This is important for 3 reasons:

 

1) This application used SK Bio's manufacturing, so it's another partner whose manufacturing is authorized. Short sellers can no longer say only SII manufacturing is authorized. It also further dispels the claims that the other Novavax locations cannot make the vaccine.

 

2) They filed for and received full approval (known as a BLA), not just an EUA, which is sometimes called "conditional marketing authorization." Experts from inside and outside of the government assessed the full filing. Full approval has requirements that are much more stringent and comprehensive, making it far harder to get. In all, Novavax is one of only 4 vaccines that have received full approval in a high-income country (HIC).

 

According to the New York Times approval tracker and this tracker, AstraZeneca (NASDAQ:AZN) hasn't received full approval in any HIC, Moderna and Johnson & Johnson have only received it in Canada, and Pfizer has received it in a few countries. The Times says Moderna is approved in Switzerland, but it's only a temporary EUA. Moderna applied in the US in June, then submitted more complete data in August. But in October the FDA said it's concerned Moderna causes myocarditis in young people and hasn't approved it.

 

Covaxin and the Russian and Chinese vaccines haven't received full approval in any country besides China and two tiny countries. So Novavax receiving full approval is a major achievement. It also indicates Novavax can file for BLA in other countries soon and receive it.

 

3) This means SK Bio doses will be going out for use soon in Korea and other countries. It means more Q1 revenues and earnings, and more exposure for Novavax. SK Bio made 40 million doses by September under its licensing contract. They passed all quality assurance steps including testing. SK Bio recorded some revenue for those in Q3. It's expected to record another $312 million (374B won) on those in Q4, plus more on delivery in Q1.

 

Under the 2nd contract in which Novavax pays a fee and keeps all profits, they also made doses by September that passed all tests. I think they've made many more since then. To ramp up production, SK Bio raised $1.26 billion via the largest IPO of the last 4 years in Korea. Its government also pledged $1.9 billion in funding to make Korea one of the biggest five vaccine manufacturers globally.

 

In Q3, SK Bio expanded their Novavax capacity by adding another production line. That increased Novavax capacity to 100 batches per annum, or 200 million doses. Last month, SK Bio and Novavax further expanded their partnership. Last week, they yet again expanded it, this time by 15%.

Several macro factors that have recently affected Novavax's share price

 

In the last two months, several macro factors having nothing to do with Novavax's sales or earnings have affected the share price negatively. These are:

 

1) A bear market in biotech: In the last 4 1/2 months, the IBB biotech ETF dropped 30% from $176 to $123.68. Just since December 23, it dropped 20% from $155.17. The XBI biotech ETF is down 36% since November 4th and down 27% since December 23rd. Also, since late December the NASDAQ dropped by 15%

 

2) In 2016, ETFs accounted for 30% of all trading by value. Since then, assets managed by ETFs increased by 168% from $3.55 trillion to $9.55 trillion. So I estimate ETFs currently make up over 40% of trading. For a company the size of Novavax that's not yet widely known, frequent selling by ETFs throws the supply / demand balance very out of whack and has an extreme effect on the price.

 

3) Novavax has long been a high-beta stock. When the market or biotech sector declines, it often drops far more. When they rise, Novavax often gains far more. Some robo-trading apps do nothing but sell high-beta names when the market or sector declines, and buy them during broad increases.

 

Among dozens of examples throughout 2021, notice that between April 27 and May 13, IBB fell 8% from a 3-month high of 157.88 to a 52-week low of 146.13. But NVAX plummeted 53% from a 3-month high of $257.67 to its 2021 low of $121. That's 6.5 times more. From there until early September, IBB rose 20% to $176, yet NVAX skyrocketed 124% to $270.8. That's 6.2x times more. Both of them peaked and bottomed at the same times, but the change in NVAX was roughly 6 times greater.

 

From there to October 27, IBB dropped 10.5% to 157.54 while NVAX dropped 48% to $141.55. From there to November 3, IBB rose 4.6% while NVAX jumped 40%. If you view the other rises and falls between those major peaks and troughs in this 1-year chart, you'll see similar co-relations usually magnified by 3 to 9 times

 

I recommend moving around the interactive comparison charts here and here to see how often Novavax gains dramatically on moderate rebounds in the sector. It shows the worst time to sell NVAX is during sector pullbacks. Likewise, buying NVAX on these pullbacks frequently gives high gains.

 

4) The current NVAX drop has been greatly exacerbated by some traders increasing their short sales during the last several weeks. For example, in the 30 days between December 15th and January 14th, 49.35% of daily volume of NVAX was short sales. That is a giant percentage.

 

5) With growing expectations for higher interest rates, investors have sold off companies that don't have earnings and won't have significant earnings until far into the future. Novavax is seen as one of them, so it's gotten hit extra hard in the last month. But that's about to change.

 

6) Fears of a hawkish Fed causing a recession have added to the current market drop.

 

These factors combined have had a major effect on the share price, but fortunately I think most of them are going to reverse in the near future.

 

Macro improvements and company-specific advances are likely on the horizon

 

Many non-fundamental traders have become attracted to Novavax. I think some saw the imbalance from the automatic ETF selling and beta selling as a trading opportunity and jumped at it. After the price bottoms, I think many of the same traders will help drive the price higher. As I detailed here, 19 major price swings occurred in the last ten months with a pullback followed by a sizable rebound each time. The sizes of most swings aren't rational, and some occur on no real news.

 

In December, Seeking Alpha contributor The Fortune Teller did a great job at describing 4 reasons why the biotech sector will probably rebound in 2022 in this article. They followed it up last week with data showing a 90% probability of a major rebound in biotechs this year.

 

They analyzed the 35 largest trading days since the biotech ETF XBI began 20 years ago. They found that a year "after an average 'large trading day', there's a 90% probability for an average return of 47%." Moreover, 7 out of the 14 days with the largest trading volumes in history occurred in the past six weeks.

 

They say that while these have been "undoubtedly rough times for those investing in biotech.... Nonetheless, this is neither the first nor the second time that biotech stocks are going through a major correction/collapse, and just as the case was in previous such events - they can, and likely are going to, recover."

 

If this probability happens and the sector rises 47%, I think high-beta biotechs like Novavax will jump far higher than that. JP Morgan also predicts the entire biotech sector will rebound this year.

 

Sector pullbacks often hit most stocks in the short-term. Later, investors analyze the companies and buy the ones that didn't deserve it. It can take a few weeks for enough fundamental investors to assess the various stocks that dropped and determine which have become good buys. But it usually happens. I think many will realize that:

 

A) Usually healthcare is only barely affected by recessions, and vaccines are especially recession-proof. They are one of the lowest-priced healthcare services, and insurers and governments cover most of the cost.

 

B) Novavax has $1.9 billion in cash and will soon have large amounts of earnings, making it a good company to own during higher rates. It also has a strong pipeline, and only a tiny amount of debt.

 

C) Pricing power is considered important during inflation. Many investors have been assuming the top Covid vaccines won't have pricing power, but over time they will understand the vaccine industry better. This comprehensive study of flu vaccine prices shows that even with many flu vaccines competing, vaccine companies consistently raise their prices to be in line with or higher than inflation. It concludes that "the prices of covid-19 vaccines are expected to rise in the coming years." Vaccines have pricing power, even when there are many vaccines for a disease.

 

In the coming weeks, Novavax will be rolled out in 27 EU countries, Australia and India. Soon after, it will probably be rolled out in the US, the UK, Canada and other countries. This will greatly increase public awareness of Novavax in those countries, which combined have a huge amount of wealth. I think some of those people will view Novavax and discover it's a strong buy. Related, an email newsletter for Novavax investors now exists, with daily updates related to the company, Covid-19 and the vaccine sector.

 

Due to the low valuation, the Motley Fool's healthcare analyst thinks US approval may cause the price to go parabolic. This quarter Novavax is also planning to file for adolescent approval in the US, plus announce results of its combination Covid-flu vaccine trial. In December, Moderna reported disappointing results for its flu shot, causing shares to tank 14%. Immune responses weren't better than existing vaccines, and even at the lowest dose, a staggering 78% of people under 50 had side effects. 13% were severe and 30.4% were medium. The next dose up caused severe side effects in 43%. It even caused side effects in 92% of people over 50.

 

I think Moderna needs to switch to smaller doses, but that would weaken immune responses even lower. If it tries to also add its Covid dose, which causes high side effects on its own, I think side effects would reach levels unacceptable to the FDA and the public. Other RNA vaccines experience similar problems when packing numerous strains into one shot. Adenovirus vaccines can't be used for multivalent shots. Sanofi, which is far behind Novavax in development of a Covid vaccine, has back-burnered work on a combination shot. So I don't see any real competition for Novavax's combination shot, which has blockbuster potential.

 

Markets are forward-looking. So I think as more approvals, production and deliveries occur, investors (and short sellers) will realize Novavax will be very profitable this quarter and dramatically profitable this year.

 

Most of the macro factors have been affecting other Covid vaccine companies, especially the higher-beta ones such as BioNTech (Nasdaq:BNTX) and Moderna. Those two have also been hurt by investors irrationally thinking that vaccine sales going forward will probably be very low. However, they are at far, far higher valuations, so I think Novavax is a far better buy. Johnson & Johnson and AstraZeneca have been partially affected by these things, but they are not high-beta names and won't benefit as much on a rebound.

 

Conclusion

 

I think Novavax is tremendously undervalued and will have a strong year. I recommend having a very over-sized position while the price is very low and taking profits gradually as the price increases. You might also consider putting a portion into call options. I recommend expirations between April and July, since by those months, the market will probably have figured out Novavax is having large revenues and earnings. I favor strike prices between $140 and $230 for those months.

 

I think even in the highly improbable scenario in which no Covid doses are needed from 2023 onwards, Novavax in 12 months would be worth more than it is now at this very low valuation. This is due to the profits from this year plus the Nanoflu vaccine, the RSV vaccines, the malaria vaccine plus other vaccines they start to do.

 

Of all drugs that enter phase 1 trials, only 14% ever make it to market. Once Nanoflu goes to market, Novavax will have two major approved products. The malaria vaccine is in phase 3 and will finish in 12 to 18 months with a very high probability of success. Both of its RSV vaccines are ready for new phase 3s, and I think the probability is high they will succeed.

I sometimes shut my eyes

I try to understand what happens

To man when he dies

No more tears no more cries

No Covishield no Cowaxin

On his death bed he lies

His body turns blue

As his soul like a bird flies

What is Man just a thought

In human disguise .

Farewell Goodbye

Narty poza Europą – najpopularniejsze ośrodki, organizacja dojazdu i ceny

 

Wyjazd na narty poza Europę wymaga lepszego przygotowania i zasobniejszego portfela – mimo to stanowi idealną okazję do odkrywania świata i poszukiwania nowych sportowych wyzwań. Sprawdziliśmy, ile zapłacimy za dojazd, karnety, ubezpieczenie i wyżywienie w najpopularniejszych ośrodkach narciarskich w USA, Kanadzie, Japonii, Gruzji i Turcji.

 

Stoki poza Starym Kontynentem, w Ameryce Północnej czy Azji są doskonale przygotowane, a infrastrukturą oraz bazą noclegową w niczym nie ustępują alpejskim ośrodkom. Niemniej jednak trzeba liczyć się z trudniejszym dojazdem (w grę wchodzi tylko samolot) oraz z wysokimi kosztami zarówno karnetów, jak i noclegów.

 

Jak zaplanować podróż na narty poza Europę?

W USA jednym z popularniejszych ośrodków jest Vail Ski Resort. 45 minut od tego kurortu znajduje się Denver International Airport, do którego można się dostać połączeniami Lufthansy z Warszawy. Lot trwa około 13 godzin, z lotniska do kurortu można dojechać wynajętym samochodem lub busem Colorado. Na narty w Kanadzie zaprasza ośrodek Whistler Blackcomb. Vancouver International Airport znajduje się 135 kilometrów od kurortu i można dotrzeć tam samolotami Air Canada, KLM i Lufthansy. Lot trwa 14-16 godzin. Przejazd z Vancouver do Whistler to około 2 godzin - można odbyć go wypożyczonym autem lub skorzystać z usług przewoźnika Epic Rides.

 

W Japonii popularnością cieszy się ośrodek narciarski Niseko United, do którego można dotrzeć połączeniami All Nippon Airways. Lot trwa 17-19 godzin, a przejazd z lotniska Sapporo-Chitose do ośrodka zajmuje około 3 godzin, aby dostać się na miejsce można wsiąść do autobusu Hokkaido Resort Liner.

 

Na narty w Gruzji najlepiej wybrać się do ośrodka w Gudauri. Samolotem LOT-u można dostać się na Tbilisi Airport, które znajduje się 143 km od ośrodka. Lot trwa niespełna 4 godziny. Przewóz z Tbilisi do ośrodka lokalnym minibusem (tzw. marszrutką) jest dostępny ze stacji autobusowej Didube i zajmuje około 2 godzin. W Turcji też można poszusować, najlepiej do tego nadaje się ośrodek Skiing Erciyes Kayseri. Lotnisko znajduje się zaledwie 22 kilometry od kurortu. To port Kayseri Erkilet International, na który można dotrzeć liniami Turkish Airlines. Lot do Kayseri trwa od 6 do 10 godzin, w zależności od przesiadki. Miasto łączy z kurortem linia autobusowa numer 4 (około 30 minut jazdy).

 

1. Vail Ski Resort (USA)

USA w czasie Pandemii - zasady wjazdu i obostrzenia

 

Do USA bez obostrzeń mogą wjeżdżać jedynie osoby w pełni zaszczepione, które w chwili odprawy lotniskowej przedstawią dowód szczepienia wystawionego zgodnie z przepisami kraju, w którym szczepienie zostało wykonane. Paszport może zostać okazany w formie papierowej lub kodu QR. Również wszyscy podróżni powyżej 2 roku życia, niezależnie od obywatelstwa i statusu szczepienia - zobowiązani są do przedstawienia negatywnego wyniku testu wykonanego na próbce pobranej w ciągu 1 dnia przed planowanym wylotem do USA.

 

Alternatywnie podróżni mogą przedstawić dokumentację ozdrowieńca, na którą składają się pozytywny wynik testu wykonanego na próbce pobranej w okresie do 90 dni przed planowanym wylotem oraz zaświadczenie od lekarza, zezwalające na podróż.

 

Małoletni cudzoziemcy (poniżej 18 roku życia) nie muszą przedstawiać zaświadczenia o szczepieniu. Niezaszczepione dzieci powyżej 2 roku życia podróżujące z zaszczepionym opiekunem/rodzicem muszą przedstawić negatywny wynik testu wykonanego 1 dzień przed planowanym wylotem do USA.

 

Należy również liczyć się z tym, że zakaz wjazdu lub ograniczenia w podróżowaniu do USA dotyczą tych, którzy nie są wcale lub nie są w pełni zaszczepieni.

 

Akceptowane szczepionki i zaświadczenia:

- jednodawkowa: Janssen/J&J

- dwudawkowe: Pfizer-BioNTech, Moderna, AstraZeneca, Covishield, BIBP/Sinopharm, Sinovac.

 

Na zaświadczeniu o szczepieniu muszą znajdować się dane osobowe: imię, nazwisko, data urodzenia identyczne jak na dokumencie podróży, data przyjęcia dawki/dawek, rodzaj szczepionki, oznaczenie organu wystawiającego zaświadczenie.

 

Osoba w pełni zaszczepiona to osoba, która otrzymała najpóźniej 14 dni przed wylotem do USA:

- dawkę akceptowanej szczepionki jednodawkowej;

- drugą dawkę akceptowanej szczepionki dwudawkowej;

- pełną serię testowanej w USA szczepionki AstraZeneca or Novavax;

- drugą dawkę szczepienia mieszanego wykonanego zaakceptowanymi szczepionkami podanymi w odstępie minimum 17 dni.

 

Vail Ski Resort - jeden z najpopularniejszych kurortów narciarskich na świecie

 

To największy ośrodek narciarski w Kolorado, a także jeden z największych tego typu obiektów na świecie. Znajduje się w niewielkiej górskiej miejscowości Vail (4589 stałych mieszkańców), gdzie roczny opad śniegu wynosi około 180 cm, a najwyższym miejscowym wzniesieniem jest Vail Mountain (3527 m n.p.m.). Sezon narciarski trwa od końca listopada do połowy kwietnia. Do największych zalet Vail Ski Resort można zaliczyć:

- 19% Zielone trasy

- 29% Niebieskie trasy

- 48% Czerwone trasy

- 4% Czarne trasy

- 195 Trasy ogółem

 

Długość tras:

- 6.4 km Najdłuższa trasa

- 2140 ha Teren narciarski

- 187 ha Sztuczne naśnieżanie

 

Ilość wyciągów:

- 2 Koleje gondolowe

- 3 Ekspresowe kanapy 6-osobowe

- 15 Ekspresowe kanapy 4-osobowe

- 1 Kanapy 4-osobowe

- 1 Kanapy 3-osobowe

- 9 Pozostałe wyciągi

 

Gdzie szusować w Vail Ski Resort?

Wśród niebieskich tras na szczególną uwagę zasługują łagodne Sourdough, Boomer, Tin Pants (spokojna nawet w weekendy) oraz Flap Jack (najdłuższa z wymienionych). Bardziej doświadczeni narciarze docenią stoki Simba, przestronny Avani (jedna z ulubionych tras okolicznych mieszkańców oraz odwiedzających ośrodek turystów, która zmienia się z niebieskiej w czarną, a następnie staje się łagodniejsza), a także Poppyfields. Na najbardziej wymagających czeka Riva Ridge (jeden z najdłuższych szlaków na Vail Mountain o długości 4 mil/6,4 km podzielona na czarne i niebieskie odcinki), oraz krótki, lecz niezwykle stromy Lovers Leap (idealny do carvingu), jak i również Forever oraz Bolshoi Ballroom.

 

Oprócz tego na terenie ośrodka znajduje się wiele otwartych terenów narciarskich, gdzie możliwa jest jazda na przełaj w stylu klasycznym (w sumie dostępna powierzchnia przekracza 8 000 akrów) – to opcja dla najbardziej zaawansowanych narciarzy.

 

Co robić po nartach w Vail?

Poza jazdą na nartach na obszarze ośrodka można uprawiać m.in. biegi narciarskie i marsze w rakietach śnieżnych (organizowane przez Vail Nordic School na okolicznych terenach), ski biking (zjazdy ze stoków na pojazdach stanowiących połączenie nart i rowerów), a także snowboard oraz jazdę skuterami śnieżnymi. Oprócz tego na gości Vail Ski Resort czekają kuligi konne, jazda psimi zaprzęgami oraz wędrówki między okolicznymi schroniskami. Vail jest ekskluzywną, otwartą na turystów miejscowością, w której znajdują się liczne kluby, luksusowe hotele, sklepy, salony spa, kina, teatry i restauracje.

Koszty wyżywienia w Vail

 

Przebywając w Vail, szczególnie warto odwiedzić Tavern on the Square (urokliwa restauracja z patio), Los Amigos (restauracja oferująca meksykańskie jedzenie oraz koktajle), Frost Bar (popularny wśród turystów bar, w którym można się napić szkockiej whisky lub egzotycznego drinka) lub Samana Lounge (jeden z najpopularniejszych klubów w okolicy).

 

W The Tap Room można zamówić różnego rodzaju zupy, pizze, kanapki i burgery za ok. 10-30 dolarów. Podobne ceny obowiązują w The Red Lion, w której serwowane są zupy, steki, dania chili i burgery. W większości miejscowych restauracji za burgera, frytki i napój zapłacimy około 20 dolarów.

 

2. Whistler Blackcomb (Kanada)

Kanada w czasie pandemii - jakie ograniczenia czekają przyjezdnych?

 

Wszyscy podróżni, niezależnie od obywatelstwa, którzy są w pełni zaszczepieni, mogą przekroczyć granicę lądową, morską i powietrzną Kanady.

 

Wybierając się na narty do Kanady, pamiętaj, że jesteś:

- zobowiązany/a do przedstawienie badania molekularnego przed wjazdem

- zobowiązany/a do korzystania z aplikacji ArriveCAN

- zobowiązany/a do przeprowadzenie testu po przybyciu, jeśli zostało zaznaczone w procedurze

- Zwolniony/a z kwarantanny

- Zwolniony/a z badania w 8. dniu po przybyciu

 

W najbliższej przyszłości (strona kanadyjska nie podaje informacji kiedy dokładnie) wszyscy w pełni zaszczepieni podróżni przybywający drogą lotniczą z krajów innych niż Stany Zjednoczone będą podlegać testom po przylocie. Wszyscy w pełni zaszczepieni podróżni będą musieli także poddać się kwarantannie w oczekiwaniu na wyniki testu.

 

Whistler Blackcomb - raj dla narciarzy

To największy tego typu obiekt w Ameryce Północnej. Whistler Blackcomb w Kolumbii Brytyjskiej to wysokiej jakości ośrodek narciarski usytuowany na zboczach gór Whistler Mountain (2 181 m. n. p. m.) i Blackcomb (2 436 m. n.p.m.), słynących z największego nachylenia stoków w Ameryce Północnej (kolejno 1 530 m i 1 565 m). Kurort utworzono łącząc Whistler i Blackcomb w 2003 roku. Ośrodek cieszy się szczególnym uznaniem wśród doświadczonych narciarzy, lecz doceniają go również amatorzy i rodziny z dziećmi. Sezon narciarski trwa tutaj od grudnia do kwietnia.

 

Jedną z największych zalet Whistler Blackcomb jest to, że każda z gór posiada unikatowy charakter. Podczas gdy Blackcomb (3,414 akrów/1,382 ha) słynie przede wszystkim z prostych, bardzo stromych stoków odpowiednich do szybkiego carvingu, Whistler (4,757 akrów/1,925 ha) pełna jest skomplikowanych, krętych dróg na których lepiej sprawdza się styl klasyczny. W sumie na terenie ośrodka znajdują się 234 szlaki narciarskie, z których najdłuższe Peak To Creek i Green Road liczą po 11 km długości każda.

 

Gdzie szusować w Whistler Blackcomb?

Początkujący narciarze docenią zalety Blue Line – łagodnego stoku, z którego rozpościera się imponujący widok na okoliczne górskie krajobrazy. Do najtrudniejszych tras należą The Couloir oraz The Cirque – obydwie o długości 0,4 km. Na szczególną uwagę zasługują również Staircase, Gun Barrels, Lakeside Bowl oraz słynąca z najwyższej jakości śniegu Surf’s Up. Podobnie jak w Vail, w Whistler Blackcomb znajduje się wiele otwartych terenów (około 50 km), optymalnych dla zaawansowanych narciarzy jeżdżących w stylu klasycznym.

Apres-ski w Whistler Blackcomb

 

Ośrodek oferuje szeroki wachlarz dodatkowych aktywności sportowych i rekreacyjnych, na które składają się marsze w rakietach śnieżnych, jazda skuterami śnieżnymi oraz heli-skiing (wyprawy w góry z wykorzystaniem helikoptera). Podobnie jak w Vail, w Whistler znajdują się liczne sklepy, restauracje, hotele i miejsca rozrywki.

Ceny wyżywienia w Whistler Blackcomb

 

Najłatwiej wypocząć w Dusty’s Bar & BBQ - jednym z najstarszych barów w mieście, w którym można posłuchać muzyki na żywo i spróbować dań BBQ. Warto zajrzeć też do Crystal Lounge (modnego klubu w centrum miasta, w którym odbywają się koncerty, konkursy karaoke i stand-upu), Brew House (miejscowej piwiarni) czy Black’s Pub (spokojnej restauracji idealnie nadającej się dla rodzin z dziećmi).

 

Wyjście do restauracji z rodziną w Whistler to koszt rzędu 90-100 dolarów kanadyjskich. W Blacks zjemy stek za 35 dolarów kanadyjskich. Podobne ceny (30-40 CAD) obowiązują w Earls, Sushi Village i Brewhouse. Do niedrogich miejsc należą Splitz Grill (burgery), Caramba! (dania serowe) i Dubh Linn Gate. Ceny posiłków zaczynają się tam już od 6-7 dolarów kanadyjskich.

3. Niseko United (Japonia)

 

Japonia w czasie pandemii - pamiętaj o zasadach

W związku z epidemią COVID-19 Japonia wprowadziła całkowity zakaz wjazdu na terytorium swojego kraju dla cudzoziemców, którzy nie posiadają wizy. O wizę można wystąpić do Ambasady Japonii w Warszawie. Wyjątkiem są cudzoziemcy posiadający status rezydenta w Japonii, którzy mogą wrócić do Japonii po uzyskaniu zaświadczenia o negatywnym wyniku testu na obecność wirusa SARS CoV-2 zrobionego w ciągu 72 godzin przed wylotem. Wynik testu musi znajdować się na stosownym formularzu.

 

Po przylocie do Japonii, na lotnisku, wykonywany jest drugi test. W przypadku, gdy okaże się on negatywny, podróżujący ma obowiązek udać są na 14-dniową kwarantannę do swojego miejsca zamieszkania (w tym celu nie wolno korzystać z transportu publicznego).

 

Niseko United - miejsce, gdzie odnajdą się początkujący i doświadczeni narciarze

To najbardziej znany japoński kurort narciarski, który co roku odwiedzają tysiące turystów z całego świata. Ośrodek usytuowany jest na wyspie Hokkaido, na stokach Niseko-Annupuri, w pobliżu niewielkiej miejscowości Niseko (liczącej zaledwie 4 938 mieszkańców). Składa się w rzeczywistości z czterech niezależnych ośrodków (Annapuri, Grand Hirafu, Hanazono i Niseko Village) objętych wspólnym skipassem. Sezon narciarski w ośrodku trwa od grudnia do maja, a miejscowe opady śniegu wynoszą ok. 590 cm. Poza licznymi stokami narciarskimi w Niseko znajdują się również źródła termalne.

 

Całkowita długość szlaków narciarskich w Niseko wynosi 55 km. Chociaż nie jest to wiele, to i tak ośrodek może poszczycić się ogromnymi terenami otwartymi o umiarkowanym stopniu nachylenia, które nadają się zarówno dla początkujących, jak i zaawansowanych narciarzy. Niseko jest jednym z niewielu ośrodków narciarskich na świecie, które umożliwiają niezapomnianą nocną jazdę po stokach.

Gdzie szusować w Niseko?

 

Na obszarze An’nupuri znajdują się przede wszystkim łagodne, niebieskie szlaki, takie jak Junior, Family i Paradise. The Hanazono to głownie trasy czerwone, przeznaczone dla średniozaawansowanych pasjonatów nart. Na narciarzy doświadczonych czekają Stairway to Heaven, Youtei Sunset oraz Crystal Garden, a także rozległe tereny poza stokami – Strawberry Fields oraz Jackson Hole. Poszukującym spokojnych i mniej zatłoczonych tras warto polecić Niseko Village, gdzie znajduje się czerwona trasa Jagaimo oraz czarna Superstition.

 

Co po nartach?

Chociaż wielu narciarzy przyjeżdża do Niseko przede wszystkim po to, aby uprawiać szybkie zjazdy na zboczu góry Annupuri, ośrodek umożliwia wiele innych aktywności sportowych i rekreacyjnych. Regularnie organizuje biegi narciarskie i marsze w rakietach śnieżnych, pozwalające na eksplorację otaczających ośrodek terenów, a także m. in. jazdę na skuterach śnieżnych, snow rafting (jazdę w pontonie po śniegu i lodzie) oraz catskiing (zjazdy na otwartych terenach po świeżym śniegu).

 

Ceny wyżywienia

Do najpopularniejszych miejsc w Niseko należą JoJo's cafe (restauracja serwująca burgery i domowe ciasta, z której rozciąga się widok na górę Yotei), Fuji Sushi (najlepsza okoliczna restauracja sushi), Bar Gyu+ (niewielki bar, w którym można napić się japońskiej whisky lub rzemieślniczego piwa) oraz The Barn by Odin (restauracja oferująca połączenie kuchni francuskiej z tradycyjnymi miejscowymi dodatkami, która mieści się w estetycznym, przeszklonym budynku).

 

Cena lunchu w Niseko wynosi około 42 zł na osobę, natomiast kolacji od 70 do 170 zł - tyle zapłaci się za wizytę w Nook Annupuri, Yotei i w Crab Shack. W Kutchan znajduje się również duży supermarket, w którego ofercie można znaleźć wszystkie podstawowe produkty spożywcze.

 

4. Gudauri (Gruzja)

To największy kurort narciarski w Gruzji, położony w południowej części Kaukazu na wysokości 2200 – 3278 m. n.p.m. W pobliżu ośrodka zaczynają się podejścia pod góry Sadzele (3260 m n.p.m.) oraz Kudebi (3008 m n.p.m). Poza różnorodnością atrakcji narciarskich turyści odwiedzający Gudauri docenią też malownicze widoki. Średnia głębokość śniegu na stokach sięga 2,5 metra, a sezon narciarski trwa od grudnia do kwietnia. Ośrodek posiada nowoczesną infrastrukturę (intensywnie rozwijaną od 1975 roku), na którą składa się duża sieć wyciągów (14 wyciągów - gondole, kanapy i orczyki), szkółki narciarskie oraz baza noclegowa i rekreacyjna. Na stokach działają również systemy sztucznego naśnieżania.

 

Powierzchnia dostępna dla narciarzy i snowboardzistów sięga niemal 3 000 hektarów. Większość terenów narciarskich opiera się na naturalnym ukształtowaniu terenu. Pasjonaci nart o różnym poziomie umiejętności mogą korzystać z 20 różnorodnych tras, a także ogromnych terenów otwartych, które nadają się do jazdy na przełaj.

Gdzie szusować w Gudauri?

 

Na terenie kurortu znajduje się wiele szlaków niebieskich (Sportuli 1 i Sportuli 2, Tatra 1 i Tatra 2) odpowiednich dla początkujących pasjonatów nart, chętnie korzystają z nich również bardziej zaawansowani narciarze. Dzięki swojej długości idealnie nadają się one do jazdy stylem klasycznym. Czerwone Kudebi 1, 2 i 3 położone są na górze Kudebi, natomiast z samego wierzchołka Sadzele odchodzi czerwona trasa Sandzele 3. Na terenie Gudauri znajdują się również trasy o większym stopniu nachylenia, odpowiednich do slalomu oraz szybkich zjazdów. Najbardziej doświadczeni narciarze i snowboardziści mają do dyspozycji czarną Sadzele, która zaczyna się przy samym szczycie góry, a także długie i proste Soliko i Guadaira.

 

Apres-ski w Gruzji

Gudauri to również wiele dodatkowych aktywności sportowych i rekreacyjnych. Goście ośrodka mogą korzystać m.in. ze snowparku, heliskiingu oraz paralotniarstwa. Regularnie organizowane są niezapomniane wyprawy skitourowe oraz zjazdy helskie. Jedną z największych miejscowych atrakcji jest eksploracja okolicznych terenów skuterami śnieżnymi lub autami terenowymi. Po całodziennym pobycie na stokach goście ośrodka Gudauri mogą wypocząć w salonie SPA lub wybrać się do jednej z wielu miejscowych restauracji, barów lub kawiarni.

Ile kosztuje wyżywienie w Gudauri?

 

Snow Time Bar (położony w centrum miasta) oferuje tradycyjne gruzińskie potrawy (chinkali i chaczapuri), dania mięsne, sałatki, drinki i koktajle. Restauracja Gamarjoba słynie z otwartej kuchni oraz potraw przygotowywanych na grillu. Można napić się w niej aromatycznego wina, a wieczorami posłuchać muzyki na żywo. Powder Bar Burjanadze (położony w górnej części Gudauri) serwuje hamburgery i steki. W ofercie baru znajdują się również rzemieślnicze piwa, nalewki i owocowe wódki.

 

Cena lunchu w Gudauri mieści się w granicach 10-40 zł za osobę. W Powder Bar za jedno zamówienie zapłacimy 8-23 zł, natomiast w AfterSkis 8-31 zł. W bardziej ekskluzywnych miejscach ceny bywają nieco wyższe. Odwiedzając restaurację Mtvrali Alubali – Drunk Cherry, trzeba przygotować się na koszty sięgające 57 zł.

 

5. Ski Erciyes Kayseri (Turcja)

Turcja w czasie pandemii - czy COVID-19 pokrzyżuje plany narciarzom?

 

Z kwarantanny zwolnione będą osoby, które wjeżdżają do Turcji z innych krajów, i we wszystkich punktach przejść granicznych, przedstawią dokument stwierdzający, że otrzymały co najmniej dwie dawki (jedna dawka szczepionki Johnson&Johnson) szczepionek zatwierdzonych przez Światową Organizację Zdrowia lub Turcję, a także, że minęło co najmniej 14 dni od ostatniej dawki.

 

Pasażerowie w wieku poniżej 12 lat są zwolnieni z raportu z testu PCR/Antygen oraz ze stosowania certyfikatu szczepionki.

 

Osoby podróżujące do Turcji są również zobowiązane do wypełnienia internetowego formularza lokalizacyjnego na maksymalnie 72 godziny przed podróżą.

Ski Erciyes Kayseri - zimowe oblicze Turcji

 

To jeden z najpopularniejszych ośrodków narciarskich w Turcji, który co roku jest odwiedzany przez dwa miliony turystów z całego świata. Erciyes znajduje się niedaleko miasta Kayseri na terenie Kapadocji – jednego z najpiękniejszych regionów Turcji, charakteryzującego się niezwykłym ukształtowaniem terenu. Ośrodek mieści się na wymarłej górze wulkanicznej Erciyes liczącej sobie 3916 m (jest to najwyższe wzniesienie w centralnej Anatolii i piąta najwyższa góra w Turcji). Większość szlaków znajduje się na wysokości od 2100 do 3360 m n.p.m. Sezon narciarski w ośrodku trwa od grudnia do kwietnia.

 

Goście kurortu mogą korzystać z nowoczesnej, stale rozwijanej infrastruktury (14 wyciągów, najdłuższy wyciąg krzesełkowy w Turcji, pierwsza ośmioosobowa gondola, wypożyczalnie sprzętu sportowego działające przy dolnych stacjach, systemy naśnieżania), a także zaawansowanej bazy noclegowo-gastronomicznej. Na terenie Erciyes znajduje się 18 tras narciarskich (łącznie niemal 102 km) o zróżnicowanym poziomie trudności.

 

Gdzie szusować w Kayseri?

Większość szlaków na terenie ośrodka (ciągnących się ponad okolicznymi lasami) oznaczono kolorem niebieskim. Leżą one przeważnie w dolnych partiach gór i nadają się dla początkujących oraz średniozaawansowanych narciarzy. W Erciyes znajduje się niemal 30 km tras czerwonych, które są w przeważającej mierze długie i proste, idealnie nadając się do szybkich zjazdów.

 

Do najbardziej wymagających tras należą Divan i Hacilar o nachyleniu około 60 stopni. W sumie na terenie Erciyes istnieje 6 czarnych stoków. Oprócz tego goście ośrodka mogą korzystać z rozległych terenów otwartych (korzystając z pomocy dostępnych na miejscu przewodników off-piste).

Co po nartach w Turcji?

 

Wizyta w Erciyes to nie tylko jazda na nartach, lecz wiele dodatkowych atrakcji. Ośrodek regularnie organizuje wyprawy skitourowe, w ramach których można dotrzeć na sam szczyt wulkanu. Oprócz tego na terenie kurortu istnieje możliwość uprawiania paralotniarstwa, jazdy konnej i trekkingu, a także wzięcia udziału w niezapomnianych spływach rzecznych oraz lotach balonem. Tylko 25 km dzieli Erciyes od Kayseri – jednego z najstarszych miast Anatolii, przesiąkniętego miejscową kulturą i pełnego bizantyjskich zabytków. W okolicy kurortu znajdują się również wydrążone w skałach domy i świątynie.

 

Ile kosztuje wyżywienie w Kayseri?

Do najpopularniejszych miejscowych restauracji należą m. in. Kardan Adam Cafe&Restaurant (śniadania, kuchnia turecka oraz dania fast food), Yörem Manti (kuchnia turecka, manti – tradycyjne tureckie pierogi), Beyaz oraz Haci Steak House (oferująca dania mięsne). Lokalnych potraw najlepiej spróbować w Gubate Restaurant ve KahvaltI Evi (szeroki wybór serów i dżemów, chałwa, dania wegetariańskie), Saray Ciftligi Kahvalti ve Yemekevi (kuchnia turecka, manti), pastirma i sucuk, dania mięsne oraz w niedrogiej Cemen's Mutfak (manti, chleb yaglama).

 

Oprócz tego na terenie ośrodka znajduje się duża strefa piknikowa, w której sprzedawane są między innymi tradycyjne regionalne kiełbaski oraz inne dania barbecue. Ceny lunchu w Erciyes wahają się w granicach 10-50 zł za osobę. W restauracji Saray Ciftligi Kahvalti ve Yemekevi zjemy już za 15 zł, natomiast koszty wizyty w Gubate Restaurant ve Kahvaltı Evi wyniosą 11-23 zł. W najbardziej luksusowych miejscach musimy być gotowi na dwa razy większe wydatki – lunch w Moda Firin & Patisserie to koszt 15-42 zł.

 

Ile kosztują skipassy poza Europą?

Bilety do każdego z omawianych ośrodków można zakupić online lub na miejscu. Najwięcej za szusowanie trzeba zapłacić w Ameryce Północnej – zarówno w USA, jak i w Kanadzie. W Vail całodzienny karnet kosztuje około 800 zł, za skipass ważny 6 dni trzeba zapłacić ponad 4 500 zł. Niewiele taniej jest w Kanadzie – jednodniowy karnet uprawniający do jazdy na nartach w Whistler Blackcomb to koszt około 500 zł, zaś za 6 dni jazdy należy zapłacić około 3000 zł. Bardziej europejskie ceny oferuje kurort Niesko United w Japonii – tam dzienny skipass to około 250 zł, zaś karnet ważny 6 dni – około 130 zł.

 

Na ceny niższe nawet niż na alpejskich czy polskich stokach można za to liczyć w Gruzji i Turcji. Za jeden dzień szusowania zapłaci się tam zaledwie około 70 zł, zaś 6-dniowy skipass kosztuje niespełna 400 zł. W Turcji jest jeszcze taniej – dzienny karnet to koszt około 50 zł, a za 6 dni szusowania zapłaci się około 300 zł.

 

Ile kosztuje nocleg poza Europą?

Ceny zakwaterowania są uzależnione od indywidualnych preferencji gości ośrodków. We wszystkich opisywanych przez nas miejscowościach istnieje rozwinięta infrastruktura noclegowa, na którą składają się prywatne domy i lokale do wynajęcia, pensjonaty i hotele. Za nocleg w ekskluzywnym, 4-gwiazdkowym hotelu najwięcej zapłacimy w Stanach Zjednoczonych (ponad 2 500 zł za dobę!), Japonii (około 1 600 zł/doba) oraz w Kanadzie (niespełna 1 000 zł/doba). Zdecydowanie taniej jest w Gruzji (nocleg w czterogwiazdkowym hotelu można mieć już za niespełna 500 zł za dobę) i Turcji (około 200 zł/doba).

 

Tańszą alternatywą są pensjonaty. Aczkolwiek w USA cena nadal odpowiada wysokiemu standardowi (ponad 2 000 zł za dobę). W Kanadzie za nocleg w pensjonacie zapłaci się około 200 zł, w Japonii jest nieco drożej – około 500 zł/doba. W Turcji doba w pensjonacie to koszt około 100 zł, jeszcze taniej jest w Gruzji – 70 zł za dobę. Szukający okazji powinni zastanowić się nad noclegiem w ramach Airbnb zapewniającym niższy standard, ale w bardzo korzystnej cenie (USA – około 800 zł/doba, Kanada – 230 zł/doba, Japonia – 300zł/doba, Gruzja – 50 zł/doba, Turcja – 40 zł/doba).

 

Koszty leczenia w USA, Kanadzie, Japonii, Gruzji i Turcji

Na terenie Europy wyjeżdżający do krajów Unii Europejskiej i EFTA mogą korzystać z publicznej służby zdrowia w ramach EKUZ. Poza Starym Kontynentem nie można liczyć na takie wsparcie – wszystkie koszty leczenia będą scedowane na pacjenta i opłacone z jego kieszeni, o ile nie posiada ubezpieczenia.

 

Nie są to małe kwoty, zwłaszcza w USA, Kanadzie czy Japonii, które należą do krajów z najwyższymi opłatami medycznymi na świecie. Za dobę spędzoną w amerykańskim szpitalu trzeba zapłacić 2 400 zł, taka sama usługa w Kanadzie to koszt o 200 zł mniejszy. Dzień w japońskim szpitalu kosztuje 1 838 zł. Za jednodniowy pobyt w szpitalu najmniej zapłaci się w Gruzji (około 100 zł) i Turcji (414 zł).

 

Sam transport powrotny w asyście lekarza lub pielęgniarki z innego kontynentu to kwestia kilkunastu tysięcy złotych. W razie konieczności dłuższego pobytu w szpitalu, wykonania specjalistycznych zabiegów medycznych oraz wykorzystania nierefundowanych leków, koszty leczenia mogą sięgać nawet kilkuset tysięcy złotych.

 

Jak wybrać ubezpieczenie na narty poza Europę?

Koszty leczenia poza Europą nie należą do najmniejszych. Aby mieć pewność, że w czasie podróży w tak odległe miejsca, jak USA, Japonia lub Turcja będziemy w stanie uzyskać dostęp do profesjonalnej pomocy medycznej, warto zdecydować się na zakup ubezpieczenia.

 

W przypadku wyprawy na narty odpowiednia polisa turystyczna zyskuje ogromne znaczenie, ponieważ aktywności sportowe mogą zwiększać ryzyko wypadków, a co za tym idzie narażając na kosztowne leczenie za granicą, kłopoty z transportem do kraju lub niedogodności związane z rozmaitymi urazami.

 

Jakie elementy powinna zawierać optymalna polisa narciarska?

- koszty leczenia – ponieważ za leczenie w USA, Kanadzie i Japonii zapłacimy dużo, powinniśmy zdecydować się na odpowiednio wysokie sumy gwarantowane, najlepiej w granicach 200 000 – 800 000 zł, w zależności od wybranego kierunku,

- koszty ratownictwa – poza Europą opłatami za akcje w górach i na stoku obciążany jest poszkodowany lub jego bliscy, ubezpieczenie pokryje te koszty w razie potrzeby,

- następstwa nieszczęśliwych wypadków (NNW) – w razie niefortunnego zdarzenia podczas jazdy na nartach czy pobytu za granicą (np. złamania nogi), ubezpieczyciel wypłaci odszkodowanie pokrywające poniesione straty (określony procent z sumy gwarantowanej),

- OC w życiu prywatnym – bardzo przydatne zwłaszcza w Kanadzie, USA i w Japonii, gdzie często dochodzi do składania pozwów przez osoby trzecie o uszkodzenia ciała i sprzętu w czasie jazdy na nartach. Zasądzane są wysokie odszkodowania, a nawet dożywotnie renty, lepiej ubezpieczyć się na wypadek takich roszczeń,

- Assistance– w ramach tej usługi ubezpieczyciel zobowiązuje się udzielić pomocy technicznej, logistycznej lub prawnej, co w wielu okolicznościach okazuje się ogromnym udogodnieniem,

- ubezpieczenie bagażu i sprzętu sportowego – w razie kradzieży, zniszczenia lub zgubienia ubezpieczyciel wypłaci stosowne odszkodowanie,

- rozszerzenie o uprawianie sportów wysokiego ryzyka/ekstremalnych – wymagane w przypadku jazdy na nartach oraz innych zimowych aktywności (w przypadku klasycznego narciarstwa wystarczą sporty wysokiego ryzyka, ale już jazda poza trasami czy heliskiing to już aktywność wymagajaca rozszerzenia o sporty ekstremalne).

 

Ile kosztuje ubezpieczenie na narty poza Europą?

Aby znaleźć optymalne ubezpieczenie w odpowiadającym naszym potrzebom przedziale cenowym, najlepiej jest skorzystać z kalkulatora dostępnego online. Po uzupełnieniu podstawowych informacji dotyczących planowanego wyjazdu, kalkulator dostępny w serwisie Rankomat.pl wygeneruje zindywidualizowaną listę ofert ubezpieczeniowych.

 

Koszt ubezpieczenia zależy od wielu czynników: kierunku i czasu podróży, liczby jej uczestników, preferowanych aktywności, wybranego zakresu. Najlepiej dopasować polisę pod kątem charakteru wyjazdu, dopasowując sumy gwarantowane do kosztów leczenia w danym kraju.

 

Ile kosztuje ubezpieczenie na narty poza Europą?

Sprawdźmy koszt ubezpieczenia turystycznego dla jednej osoby na 7-dniowy wyjazd do poszczególnych kurortów narciarskich.

 

Polisę na narty poza Europą można mieć już od 2, 20 zł dziennie. Warto jednak zdecydować się na optymalną ochronę, która zapewni bezpieczny wyjazd i pobyt za granicą. Po wyborze konkretnej oferty, polisę można zakupić bezpośrednio na stronie – umowa ubezpieczenia zostanie przesłana na adres e-mail, wystarczy ją pobrać, wydrukować i zabrać ze sobą na stok.

 

"Odpowiednie ubezpieczenie na nartach to jedna z najważniejszych spraw, o których nie możemy zapomnieć. Narciarstwo zaliczane jest do najniebezpieczniejszych sportów na świecie, a polisa zapewnia ochronę, dzięki której podczas wszelkiego rodzaju wypadków, czy uszkodzeń, możemy czuć się bezpiecznie. Kalkulator ubezpieczeń turystycznych na rankomat.pl to prosta i intuicyjna porównywarka, która pozwala za pośrednictwem kilku kliknięć znaleźć doskonale dopasowane ubezpieczenie do indywidulanych oczekiwań" - mówi Patrycja Pałka, specjalista ds. ubezpieczeń turystycznych na rankomat.pl

 

Narty poza Europą – czy warto?

Chociaż organizacja wizyty w kurorcie na innym kontynencie jest nieco bardziej skomplikowana od wczasów na południu lub zachodzie Europy, nie sposób przecenić jej walorów – stanowi ona nie tylko okazję do poszukiwania nowych narciarskich wrażeń, wypoczynku w luksusowych warunkach oraz korzystania z najlepszej infrastruktury narciarskiej na świecie, lecz również poznania nowych miejsc. W rezultacie narty poza Europą są dobrym pomysłem na urlop dla wszystkich pasjonatów sportów zimowych oraz wielbicieli zimowej atmosfery.

 

Co warto wiedzieć?

1. Do najpopularniejszych ośrodków poza Europą należą Vail Ski Resort (USA), Whistler Blackcomb (Kanada), Niseko United (Japonia), Gudauri (Gruzja) oraz Ski Erciyes Kayseri (Turcja).

 

2. Koszt podróży na narty poza Europę waha się, w zależności od wybranego kierunku, od 800 zł do 3 000 zł.

 

3. Najwięcej jazda na nartach kosztuje w USA oraz Kanadzie, nieco taniej jest w Japonii. Na tureckich i gruzińskich stokach można szusować taniej niż w Polsce.

 

4. Poza Europą nie działa EKUZ - za leczenie trzeba zapłacić z własnej kieszeni. Trzeba liczyć się z wydatkiem od 400 zł do 2 400 zł za dobę w szpitalu.

 

5. Ubezpieczenie na narty poza Europą, które pokryje wszystkie wydatki związane z leczeniem oraz nieszczęśliwymi wydarzeniami za granicą można mieć już od 7,27 zł do 22,11 zł dziennie.

Foto: Breno Esaki/Agência Saúde DF

www.reuters.com/world/us/exclusive-us-opposes-plans-stren...

 

U.S. opposes plans to strengthen World Health Organization

 

Major funding reform supported by Europe, Africa, South Asia

White House proposes separate fund for health emergencies

Biden administration sceptical about WHO, sources say

 

BRUSSELS, Jan 21 (Reuters) - The United States, the World Health Organization's top donor, is resisting proposals to make the agency more independent, four officials involved in the talks said, raising doubts about the Biden administration's long-term support for the U.N. agency.

 

The proposal, made by the WHO's working group on sustainable financing, would increase each member state's standing annual contribution, according to a WHO document published online and dated Jan. 4.

 

The plan is part of a wider reform process galvanised by the COVID-19 pandemic, which has highlighted the limitations of the WHO's power to intervene early in a crisis.

 

But the U.S. government is opposing the reform because it has concerns about the WHO's ability to confront future threats, including from China, U.S. officials told Reuters.

 

It is pushing instead for the creation of a separate fund, directly controlled by donors, that would finance prevention and control of health emergencies.

 

Four European officials involved in the talks, who declined to be named because they were not authorised to speak to the media, confirmed the U.S. opposition. The U.S. government had no immediate comment.

 

The published proposal calls for member states' mandatory contributions to rise gradually from 2024 so they would account for half the agency's $2 billion core budget by 2028, compared to less than 20% now, the document said.

 

The WHO's core budget is aimed at fighting pandemics and strengthening healthcare systems across the world. It also raises an additional $1 billion or so a year to tackle specific global challenges such as tropical diseases and influenza.

 

Supporters say that the current reliance on voluntary funding from member states and from charities such as the Bill and Melinda Gates Foundation forces the WHO to focus on priorities set by the funders, and makes it less able to criticise members when things go wrong.

 

An independent panel on pandemics that was appointed to advise on the WHO reform had called for a much bigger increase in mandatory fees, to 75% of the core budget, deeming the current system "a major risk to the integrity and independence" of the WHO.

 

LONG-STANDING SCEPTICISM

 

The WHO itself responded to a query by saying that "only flexible and predictable funds can enable WHO to fully implement the priorities of the Member States".

 

Top European Union donors, including Germany, back the plan, along with most African, South Asian, South American and Arab countries, three of the European officials said.

 

The proposal is to be discussed at the WHO's executive board meeting next week but the divisions mean no agreement is expected, three of the officials said.

 

The WHO confirmed there was currently no consensus among member states, and said talks were likely to continue until the annual meeting in May of the World Health Assembly, the agency's top decision-making body.

 

European donors in particular favour empowering, rather than weakening, multilateral organisations including the WHO.

 

One European official said the U.S. plan "causes scepticism among many countries", and said the creation of a new structure controlled by donors, rather than by the WHO, would weaken the agency's ability to combat future pandemics.

 

Washington has been critical of the WHO for some time.

 

Former president Donald Trump pulled the United States out of the WHO after accusing it of defending China's initial delays in sharing information when COVID-19 emerged there in 2019.

 

The Biden administration rejoined soon after taking office, but officials told Reuters they think the WHO needs significant reform, and raised concerns about its governance, structure and ability to confront rising threats, not least from China.

 

One of the European officials said other big countries, including Japan and Brazil, were also hesitant about the published WHO proposal.

 

Two of the European officials said China had not yet made its position clear, while a third official listed Beijing among the critics of the proposal.

 

The governments of Japan, China and Brazil had no immediate comment.

  

finance.yahoo.com/news/sorrento-therapeutics-announces-co...

 

Sorrento Therapeutics Announces Covishield (Sti-9167), a Broad-Spectrum Neutralizing Antibody, Potently Neutralizes Omicron and Omicron (+R346k) Variants of Sars-Cov-2

 

COVISHIELD (STI-9167) neutralizing antibody (nAb) was discovered by scientists from the Icahn School of Medicine at Mount Sinai (“Icahn Mount Sinai”) and further optimized and engineered by Sorrento scientists.

 

A preprint manuscript is published online at biorxiv.org: biorxiv.org/cgi/content/short/2022.01.19.476998v1

 

Sorrento has obtained worldwide exclusive license rights from Icahn Mount Sinai as previously announced on March 9, 2021

 

Compared to available published literature and head-to-head experiments, STI-9167 nAb is a potentially “Best-in-Class” nAb against the Omicron variant of SARS-CoV-2 and the first reported nAb with high potency against Omicron (+R346K mutation) and has demonstrated highly potent neutralization activities in vitro (IC50 of 25 ng/mL for Omicron live virus, 14.8 ng/mL and 23.9 ng/mL for Omicron and Omicron (+R346K mutation) pseudovirus, respectively), in addition to potent neutralizing activities against the SARS-CoV-2 virus and all of its variants of concern (VOCs).

 

STI-9167 nAb demonstrated strong protection in vivo following Omicron virus challenge in a preclinical model of COVID-19, preventing weight loss and reducing virus titers in the lungs to levels below the limit of detection.

 

GMP drug product manufacturing in support of large clinical development is in place at Sorrento GMP facilities.

 

Sorrento is evaluating in-house GMP manufacturing and is in negotiations with major global CMOs for commercial scale manufacturing to secure capacity to manufacture and supply tens of millions of doses. Sorrento currently has in-hand sufficient cGMP drug substance for 100,000’s of doses at the projected intranasal dose of STI-9199, the intranasal formulation of STI-9167.

 

INDs to be submitted in the US, UK and Mexico within a month for use as either a small volume intravenous push or intranasal instillation.

 

(investors.sorrentotherapeutics.com/news-releases/news-rel...).

 

SAN DIEGO, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the release of new data on the Omicron variant neutralizing antibody (nAb) STI-9167, COVISHIELD, an advanced stage antibody discovered and developed for clinical trials in an ongoing collaboration between immunologists and virologists at Sorrento and the Icahn School of Medicine at Mount Sinai (“Icahn Mount Sinai”) in New York, NY.

 

Spike protein binding assays and neutralization assays using viruses representing all known SARS-CoV-2 variants of concern (VOCs) have been completed with STI-9167, and this nAb was observed to bind with high affinity and provide highly potent neutralizing activity (Omicron IC50 = 25 ng/ml). Of noted significance, STI-9167 is unique when compared to tests of EUA-approved SARS-CoV-2 nAbs in that binding and neutralization properties are maintained against the emerging Omicron and Omicron (+R346K) variant, an increasingly prevalent Omicron lineage variant that encodes an additional R346K Spike protein mutation. Additionally, STI-9167 administered at a low dose (5mg/kg) by either the intranasal or intravenous routes provided strong protection against the clinical signs of infection by the Omicron variant in the K18-hAce2 transgenic mouse model of COVID-19, preventing weight loss and reducing virus titers in the lungs to undetectable levels.

 

“The generation and characterization of the STI-9167 nAb demonstrates the great collaboration between the scientists of Mount Sinai and Sorrento to address a global health crisis,” said Domenico Tortorella, PhD, Professor of Microbiology at Icahn Mount Sinai.

 

“We selected antibody STI-9167 from large sets of diverse anti-SARS-CoV-2 spike neutralizing antibodies that we developed in our labs. It demonstrated the most effective cross-neutralization against all known SARS-CoV-2 isolates and variants of concerns, including the recent Omicron and Omicron (+R346K) variants,” commented J. Andrew Duty, PhD, Assistant Professor of Microbiology and Director of the Center for Therapeutic Antibody Development at Icahn Mount Sinai.

 

“The currently EUA-approved nAbs have markedly reduced or absent binding and neutralization activities against omicron/omicron (+R346K) making them inadequate to support current clinical needs,” stated Mike A. Royal, MD, JD, MBA, Chief Medical Officer at Sorrento. “Alternative nAbs are sorely needed in the near term, particularly for the pediatric population which appears to be at higher risk for severe omicron infection and hospitalization. Our intranasal COVIDROPS formulation delivers our nAbs to the upper airways where Omicron is most likely to target and flourish, and as a non-invasive, easy to administer treatment, it is ideal for children. We have already begun to treat children with COVIDROPS (with STI-2099) in Mexico where the delta variant is still prevalent. Through Phase 2 studies in the US, United Kingdom and Mexico, we have seen a benign safety profile for intranasal delivery of our nAbs and expect a similar outcome with COVIDROP (with STI-9167).”

 

“We now have had experience with bringing multiple COVID-19 therapeutics into the clinic and advancing several into Phase 2 and/or pivotal development,” says Mark Brunswick, PhD, SVP and Head of Regulatory Affairs and Quality at Sorrento. “We are well situated to rapidly bring forth COVISHIELD through the IND stage and into the clinic and expect to file this important IND in the next month.”

 

Dr. Henry Ji, Chairman and CEO of Sorrento, commented, “The work by the teams at Sorrento and Mount Sinai has yielded a remarkable antibody with unique and valuable protective properties against Omicron and all other SARS-CoV-2 VOCs. Our COVISHIELD neutralizing antibody is the best-in-class and the most advanced candidate for combatting the prevalent Omicron and emerging Omicron (+R346K) VOCs. We are working diligently to position this antibody for use in COVID patients and are confident that our approach will provide an efficacious clinical solution not only in the near term but also as the pandemic continues to evolve.”

 

A preprint manuscript is published online at biorxiv.org: biorxiv.org/cgi/content/short/2022.01.19.476998v1

 

The neutralizing antibody described was generated in the laboratories at Mount Sinai and exclusively licensed to Sorrento Therapeutics. Mount Sinai and Mount Sinai faculty members have a financial interest in Sorrento Therapeutics.

 

About STI-9167, COVISHIELD, Antibody

 

Initially isolated as a SARS-CoV-2 (WA-1 strain) nAb candidate following vaccination of transgenic mice, the STI-9167 antibody was optimized to maximize protein stability and minimize interactions with host Fc gamma receptors. Using established master cell banks, GMP drug product has been generated at Sorrento in preparation for anticipated Phase 1 through pivotal Phase 2/3 human clinical trials. Tech transfer of methods and GMP processes in support of commercial-scale GMP manufacturing is currently underway.

 

About STI-9167 Clinical Development Plans

 

Sorrento has demonstrated the protective effects of SARS-CoV-2 nAbs administered by either intravenous, IV, or intranasal, IN, routes in preclinical COVID-19 animal models and the safety of SARS-CoV-2 nAbs administered by IV and IN routes to human subjects. Current clinical study plans for STI-9167, pending feedback from regulatory agencies, call for evaluation of safety following antibody administration at single doses via the IV and IN routes in healthy normal adults or asymptomatic Omicron infected patients, followed by large Phase 2/3 clinical trials globally for newly infected COVID-19 patients.

inicio del plan de vacunación contra COVID 19 en la ciudad de Buenos Aires / 23-02-2021

www.nih.gov/news-events/news-releases/study-confirms-link...

 

Study confirms link between COVID-19 vaccination and temporary increase in menstrual cycle length

Large NIH-funded study included participants in North America and Europe.

 

A large international study has confirmed the findings of a previous U.S. study that linked COVID-19 vaccination with an average increase in menstrual cycle length of less than one day. The increase was not associated with any change in the number of days of menses (days of bleeding). Funded by the National Institutes of Health, the new study included data from nearly 20,000 people from Canada, the United Kingdom, the United States, Europe and other parts of the world who received any of nine different vaccines. For most study participants, the increase resolved in the cycle following vaccination.

 

The study’s principal investigator was Alison Edelman, M.D., M.P.H., of Oregon Health & Science University in Portland. It appears in the BMJ Medicine.

 

“These findings provide additional information for counseling women on what to expect after vaccination,” said Diana Bianchi, M.D., director of NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). “Changes following vaccination appear to be small, within the normal range of variation, and temporary.”

 

NICHD and NIH’s Office of Research on Women’s Health funded the study, which was part of $1.67 million awarded to five institutions to explore potential links between COVID-19 vaccination and menstrual changes.

 

A change in cycle length of less than eight days is considered within the normal range of variation. Although small menstrual changes may not be meaningful to health care professionals and researchers, the study authors wrote, perceived changes in a bodily function linked to fertility may be alarming to those experiencing it and could contribute to vaccine hesitancy.

 

Researchers analyzed de-identified data from the fertility tracking app, Natural Cycles. Users of the app provided it information on their temperature and their menstrual cycles. They also had the option to consent to the use of their de-identified data for research. Worldwide rollout of COVID-19 vaccines allowed the study authors to expand on their original study of people in the United States. The study included data from participants throughout the world, but most were from the United Kingdom (32%), the United States and Canada (29%) and Europe (34%). In addition to the messenger RNA COVID-19 vaccines (Pfizer-BioNTech and Moderna), participants received COVID-19 vaccines made from engineered viruses (AstraZeneca, Covishield, Janssen/Johnson & Johnson and Sputnik), and inactivated viruses (Covaxin, Sinopharm, and Sinovac).

 

A total of 19,622 individuals participated. Of these, 14,936 were vaccinated and 4,686 were not. The researchers analyzed data on at least three consecutive cycles before vaccination and at least one cycle after. Data from at least four consecutive cycles were analyzed over a similar time interval for unvaccinated participants.

 

On average, vaccinated people experienced an increase of less than one day in each cycle in which they were vaccinated: a .71 day increase after the first dose and a .56 day increase after the second dose. Participants who received both doses in a single cycle had a 3.91 day increase in cycle length. After vaccination, cycle length had increased by only .02 days for individuals who received one dose per cycle, and .85 days for individuals who received two doses in one cycle, compared to participants who were not vaccinated. Changes in cycle length did not differ according to the type of vaccine received.

 

Of the total, 1,342 participants experienced a change in cycle length of eight or more days, comprising 6.2% of vaccinated individuals and 5.0% of unvaccinated individuals. Women who were younger and who had longer cycle length before vaccination were more likely to experience the increase.

 

The authors called for future studies on other aspects of vaccination-linked changes to menstrual cycles, such as unexpected vaginal bleeding and menstrual flow and pain. They also called for studies to determine the physical reasons why such changes might occur.

 

www.cnn.com/2022/09/27/health/uk-fall-wave-covid-us/index...

 

Rising Covid-19 cases in the UK may be a warning for the US

 

There are signs that the United Kingdom could be heading into a fall Covid-19 wave, and experts say the United States may not be far behind.

 

A recent increase in Covid-19 cases in England doesn’t seem to be driven by a new coronavirus variant, at least for now, although several are gaining strength in the US and across the pond.

 

“Generally, what happens in the UK is reflected about a month later in the US. I think this is what I’ve sort of been seeing,” said Dr. Tim Spector, professor of genetic epidemiology at Kings College London.

 

Spector runs the Zoe Health Study, which uses an app to let people in the UK and US report their daily symptoms. If they start to feel bad, they take a home Covid-19 test and record those results. He says that about 500,000 people are currently logging their symptoms every day to help track trends in the pandemic.

 

Spector says the study, which has been running since the days of the first lockdown in England in 2020, has accurately captured the start of each wave, and its numbers run about one to two weeks ahead of official government statistics.

 

After seeing a downward trend for the past few weeks, the Zoe study saw a 30% increase in reported Covid-19 cases within the past week.

 

“Our current data is definitely showing this is the beginning of the next wave,” Spector said.

 

On Friday, that increase was reflected in official UK government data too, although it was not as large as the increases reported by Zoe loggers.

 

Data from the National Health Service showed that after falling for nearly two months, the seven-day average of new cases in England and Wales rose 13% for the week ending September 17 over the week before. The seven-day average of hospitalizations was up 17% in the week ending September 19 compared with the week prior.

 

The data aligns with what models have predicted would happen in both the UK and the US.

 

“They predicted that we’d get a June to July peak and then there’d be a month where nothing happened in August and then it would flatten in in August and September and then start again in October. So it’s exactly matching what the modelers have have been predicting,” Spector said.

 

In the US, some models have predicted that Covid-19 cases will begin to rise again in October and continue to increase into the winter. Experts are hopeful that because most of the population now has some underlying immunity to the coronavirus, this wave would be less deadly than we’ve seen in previous winters.

 

Is this a blip or a wave?

 

It’s not clear what’s driving the increase in the UK or whether it will be sustained.

 

“These trends may continue for more than a week or two, or they may not,” said Kevin McConway, emeritus professor of applied statistics at the Open University in Milton Keynes, England.

 

Broken down by age, he says, there are clear increases among adolescents who are around middle school age and younger adults, those 25 through 34.

 

“It wouldn’t be surprising if there were some increase in infection as people come back from summer holidays and as the schools reopen,” McConway said in a statement to the nonprofit Science Media Centre. “Even if it is, there’s certainly no clear indication yet that it will continue.”

 

He’s not the only one who needs to see more data before calling this the start of a new wave.

 

“Question one is, how significant is that rise? Is it, for instance, the beginning of something, a new wave, or is this a temporary blip because of all of the getting together around the Queen’s funeral and other events that have been going on?” said Dr. Peter Hotez, who co-directs the Center for Vaccine Development at Texas Children’s Hospital in Houston.

 

A second important question will be whether the increase is being driven by a new variant.

 

“That’s the worst possible situation. Because historically, when that situation occurs in the UK, it’s reflected within a matter of weeks in the United States,” Hotez said. “That was true of the Alpha wave; that was true of the Delta wave; that was true of Omicron and its subvariants.”

 

The role of new variants

 

That’s where the US may catch a break this time around.

 

Instead of new variants, Christina Pagel, a professor of operational research at University College London, thinks cases are going up in the UK because of a combination of waning immunity and behavioral changes.

 

Many people in the UK are several months past their last Covid-19 booster or infection, and government statistics show that just 8% of adults 50 and older have gotten an Omicron-specific vaccine since the government started its fall vaccination campaign in September. School and work have fully resumed after the summer holidays, and people are spending more time indoors as the temperature drops.

 

Immunity is also waning in the United States, and Americans have also been slow to get boosted. Just 35% of those for whom a booster is recommended have had one, according to CDC data.

 

The updated boosters in the US are slightly different from the ones in the UK. The UK is using vaccines that have been updated to fight the original version of Omicron, which is not circulating anymore. US boosters have been updated to fight the BA.4 and BA.5 subvariants, which are currently causing infections both here and abroad. It’s not clear whether the strain differences will have an effect on cases or disease severity.

 

There are a mix of new variants – offshoots of BA.4 and BA.5 – that are waiting in the wings. They represent just a small proportion of total cases, but several are growing against BA.5, which is still dominating transmission.

 

“It is very likely that these will accelerate current increases and cause a substantial wave in October” in the UK, Pagel said in an email to CNN.

 

Other experts agree with that assessment.

 

“There is talk about a bunch of lineages with concerning mutations, including BA.2.75, BQ.1.1, etc, but none of these are of high enough frequency in the UK right now to be driving the change in cases,” Nathan Grubaugh, who studies the epidemiology of microbial diseases at the Yale School of Public Health, said in an email to CNN.

 

He says the mix of variants in the UK seems to be much the same as it is in the US, at least for now.

 

“We are seeing the increase in many respiratory viruses right now in the US, so it’s not a stretch to think that a new COVID wave (or ripple) will be coming soon,” he wrote.

#ВакцинаціяпротиCOVID-19

#Убезпеці

Місце зйомки: м. Київ, Україна

Фотограф: Олександр Жадан

Vyshgorod/ Oleksandr Zhadan

#ВакцинаціяпротиCOVID-19

#Убезпеці

Місце зйомки: Вишгород, Київська обл., Україна

Фотограф: Олександр Жадан

Vyshgorod/ Oleksandr Zhadan

#ВакцинаціяпротиCOVID-19

#Убезпеці

Місце зйомки: м. Київ, Україна

Фотограф: Олександр Жадан

Vyshgorod/ Oleksandr Zhadan

#ВакцинаціяпротиCOVID-19

#Убезпеці

Місце зйомки: м. Київ, Україна

Фотограф: Олександр Жадан

Vyshgorod/ Oleksandr Zhadan

#ВакцинаціяпротиCOVID-19

#Убезпеці

Місце зйомки: м. Київ, Україна

Фотограф: Олександр Жадан

Vyshgorod/ Oleksandr Zhadan

#ВакцинаціяпротиCOVID-19

#Убезпеці

Місце зйомки: м. Київ, Україна

Фотограф: Олександр Жадан

Vyshgorod/ Oleksandr Zhadan

#ВакцинаціяпротиCOVID-19

#Убезпеці

Місце зйомки: м. Київ, Україна

Фотограф: Олександр Жадан

Vyshgorod/ Oleksandr Zhadan

#ВакцинаціяпротиCOVID-19

#Убезпеці

Місце зйомки: м. Київ, Україна

Фотограф: Олександр Жадан

Vyshgorod/ Oleksandr Zhadan

#ВакцинаціяпротиCOVID-19

#Убезпеці

Місце зйомки: Вишгород, Київська обл., Україна

Фотограф: Олександр Жадан

Vyshgorod/ Oleksandr Zhadan

All vaccines, except Pfizer vaccines, can be kept at two to eight degree Celsius temperatures. Pfizer vaccines have to be kept at temperatures below minus 70 degrees Celsius.

 

The crisis of Corona virus (Covid-19) is not over yet. At the same time, vaccination of corona vaccine is going to start soon in the country for the prevention of corona virus. Kovishield and Kovaxin have been approved for the Corona virus vaccine in the country. Both vaccines have been prepared in India, while both these vaccines are much cheaper than other Corona vaccines made in the world.

  

Union Health Secretary Rajesh Bhushan said that in addition to 1.1 crore doses of Kovishield from Serum Institute of India, 55 lakh doses of Covaxine are being purchased from Bharat Biotech. He said that 55 lakh doses of covaxine are being purchased from Bharat Biotech. Each of the 38.5 lakh doses of covaxine will cost Rs 295 (taxed). At the same time, Bharat Biotech is providing 16.5 lakh doses free, so that its cost will be Rs 206 for each dose. At the same time, the Government of India has purchased 200 rupees per dose from Serum Institute of India. Tax is not included in the price of 200 rupees of this vaccine. The price of KoviShield is 210 rupees (after tax) in India.

 

This is the cost of another Corona vaccine

  

The corona virus is being seen all over the world. At the same time, vaccination of corona vaccine has also started in many countries. Meanwhile, when compared to the prices of Corona vaccine present in the world, Corona vaccine is becoming available in India at very cheap rates. Talking about the prices of vaccines available in the world, Union Health Secretary Rajesh Bhushan said that the cost of Pfizer-BioNotech vaccine comes to Rs 1431 per dose. At the same time, the price of Moderna vaccine is from Rs 2348 to Rs 2715, the price of Novavax vaccine is Rs 1114, the price of Sputnik-V vaccine is Rs 734 and the vaccine manufactured by Johnson & Johnson is Rs 734. Apart from this, the price of Chinese Sinoform Vaccine is 77 US Dollars per dose, that is, doses are available at a price of more than Rs 5650.

  

Apart from this, maintenance of corona vaccine is also very important. Especially the Pfizer's Corona vaccine requires a much lower temperature. Rajesh Bhushan said that all vaccines except Pfizer vaccine can be kept at two to eight degree Celsius temperature. Pfizer vaccines have to be kept at temperatures below minus 70 degrees Celsius.

  

Vaccination from 16 January

  

The central government informed that 54.72 lakh doses of Kovid-19 vaccine have been delivered to the scheduled national and state level storage centers by Tuesday afternoon and by January 14, 1.1 crore from Serum Institute of India and 55 lakh doses from Bharat Biotech. Let us know that as part of the decisive battle against the corona virus, vaccination campaign is being started in the country from 16 January.

 

Visit: newstimeindia.in/india-news/corona-vaccine-price-cheapest...

 

#ВакцинаціяпротиCOVID-19

#Убезпеці

Місце зйомки: Вишгород, Київська обл., Україна

Фотограф: Олександр Жадан

Vyshgorod/ Oleksandr Zhadan

#ВакцинаціяпротиCOVID-19

#Убезпеці

Місце зйомки: Вишгород, Київська обл., Україна

Фотограф: Олександр Жадан

Vyshgorod/ Oleksandr Zhadan

Foto: Breno Esaki/Agência Saúde DF

Foto: Breno Esaki/Agência Saúde DF

#ВакцинаціяпротиCOVID-19

#Убезпеці

Місце зйомки: Вишгород, Київська обл., Україна

Фотограф: Олександр Жадан

Vyshgorod/ Oleksandr Zhadan

Foto: Breno Esaki/Agência Saúde DF

Foto: Breno Esaki/Agência Saúde DF

Foto: Breno Esaki/Agência Saúde DF

#ВакцинаціяпротиCOVID-19

#Убезпеці

Місце зйомки: Вишгород, Київська обл., Україна

Фотограф: Олександр Жадан

Vyshgorod/ Oleksandr Zhadan

Foto: Breno Esaki/Agência Saúde DF

Foto: Breno Esaki/Agência Saúde DF

Foto: Breno Esaki/Agência Saúde DF

Foto: Breno Esaki/Agência Saúde DF

Foto: Breno Esaki/Agência Saúde DF

Foto: Breno Esaki/Agência Saúde DF

inicio del plan de vacunación contra COVID 19 en la ciudad de Buenos Aires / 23-02-2021

Foto: Breno Esaki/Agência Saúde DF

Foto: Breno Esaki/Agência Saúde DF

Foto: Breno Esaki/Agência Saúde DF

inicio del plan de vacunación contra COVID 19 en la ciudad de Buenos Aires / 23-02-2021

Foto: Breno Esaki/Agência Saúde DF

inicio del plan de vacunación contra COVID 19 en la ciudad de Buenos Aires / 23-02-2021

inicio del plan de vacunación contra COVID 19 en la ciudad de Buenos Aires / 23-02-2021

inicio del plan de vacunación contra COVID 19 en la ciudad de Buenos Aires / 23-02-2021

FILE PHOTO: People wait to receive a dose of COVISHIELD, a COVID-19 vaccine manufactured by Serum Institute of India, in Mumbai, India, March 1, 2021. REUTERS/Francis Mascarenhas/File Photo

inicio del plan de vacunación contra COVID 19 en la ciudad de Buenos Aires / 23-02-2021

परोपकारार्थं इदं शरीरं

This life is to help others

 

Healing Hands Foundation successfully vaccinated 77 members of The National Federation Of The Blind at Shrikrisha Temple, Nigdi, on 7 June 2021.

 

The camp was organised by Dr. Ashwin Porwal and Dr. Snehal Porwal, President and Secretary, Healing Hands Foundation.

 

On behalf of HHF, Madhura Bhate(NGOCoordinator, HHF), Anita Said, Pooja Rao, Tejashree Khalate, Anuja Kadam, Rasika Tambe, and the vaccination team successfully carried out the vaccination program.

 

Lack of awareness and understanding about vaccines makes many of them hesitant towards it.

This small initiative also helped us to remove the misconceptions in the minds of many during this drive.

 

निगडी येथील श्रीकृष्ण मंदिर येथे हीलिंग हॅन्डस फॉउंडेशन मार्फत दि नॅशनल फेडरेशन ऑफ ब्लाइंड संस्थेच्या 77 अंध व्यक्तींचे कोविशिल्ड लशी चे मोफत लसीकरण 7 जून 2021 रोजी करण्यात आले.

 

हीलिंग हँड्स फाउंडेशन चे अध्यक्ष डॉ.अश्विन पोरवाल व सचिव डॉ.स्नेहल पोरवाल यांनी सदर शिबिराचे आयोजन केले.

 

हीलिंग हँड्स फाउंडेशन च्या वतीने सौं.मधुरा भाटे (संस्था सामन्वयक), सौं.अनिता सैद, तेजश्री खलाटे, सौं.पूजा राव,अनुजा कदम, रसिका तांबे आणि टीम ने लसीकरण उपक्रम यशस्वीपणे राबविले.

 

लसीकरणा दरम्यान अनेकांच्या मनातले असणारे गैरसमज दूर करून त्यांच्या पर्यंत सुविधा मोफत पोहोचवण्याचा संस्थे तर्फे राबविण्यात आलेला हा एक छोटासा उपक्रम.

 

Healing Hands Foundation, Pune, and Divyang Vikas Sanstha Talegaon Dabhade, jointly organized a free second dose vaccination drive for the physically abled.

 

The drive was organized at P.H.C Talegaon.

 

Total 55 beneficiaries were able to avail the benefit of the vaccination drive.

 

Nurse Shivani Tekade and Nurse Omkar Shinde administered the vaccine on behalf of Healing Hands Foundation, Counselor Tejashree Khalate registered and guided them. Camp coordinator Anita Said managed the complete drive under the guidance of NGO Coordinator Madhura Bhate.

 

Members of Divyang Vikas Sanstha Kiran Karpe, Kishor Dighe, Prithviraj Chavan, and Kishor Kulkarni supported the drive and bought all beneficiaries together.

 

The camp received special support from villagers, Zilla Parishad Health Department, and Gram Panchayat.

  

Healing Hands Foundation, Pune, and Divyang Vikas Sanstha Talegaon Dabhade, jointly organized a free second dose vaccination drive for the physically abled.

 

The drive was organized at P.H.C Talegaon.

 

Total 55 beneficiaries were able to avail the benefit of the vaccination drive.

 

Nurse Shivani Tekade and Nurse Omkar Shinde administered the vaccine on behalf of Healing Hands Foundation, Counselor Tejashree Khalate registered and guided them. Camp coordinator Anita Said managed the complete drive under the guidance of NGO Coordinator Madhura Bhate.

 

Members of Divyang Vikas Sanstha Kiran Karpe, Kishor Dighe, Prithviraj Chavan, and Kishor Kulkarni supported the drive and bought all beneficiaries together.

 

The camp received special support from villagers, Zilla Parishad Health Department, and Gram Panchayat.

  

Healing Hands Foundation, Pune, and Divyang Vikas Sanstha Talegaon Dabhade, jointly organized a free second dose vaccination drive for the physically abled.

 

The drive was organized at P.H.C Talegaon.

 

Total 55 beneficiaries were able to avail the benefit of the vaccination drive.

 

Nurse Shivani Tekade and Nurse Omkar Shinde administered the vaccine on behalf of Healing Hands Foundation, Counselor Tejashree Khalate registered and guided them. Camp coordinator Anita Said managed the complete drive under the guidance of NGO Coordinator Madhura Bhate.

 

Members of Divyang Vikas Sanstha Kiran Karpe, Kishor Dighe, Prithviraj Chavan, and Kishor Kulkarni supported the drive and bought all beneficiaries together.

 

The camp received special support from villagers, Zilla Parishad Health Department, and Gram Panchayat.